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ABSTRACT

The adipose tissue functions as the body’s main energy reservoir and plays a central
role in maintaining whole body energy homeostasis. The ability to modulate this tissue’s
inherent endocrine and metabolic functions has promising implications in treating disease
associated with adipose tissue dysfunction. This work revolves around two diseases where
adipose tissue inflammation and metabolic dysfunction drive the disease, obesity and
cachexia. Both diseases impact a significant population of U.S. adults and substantially
reduce patient quality of life.
In this study, we first demonstrate the use of novel therapeutic platforms engineered
to specifically target adipose tissue inflammation and lipid catabolism through localized
drug delivery for the treatment of obesity. Specifically, we developed poly(lactide-coglycolide) scaffolds loaded with resveratrol, a small molecule with promising anti-obesity
and anti-inflammatory properties, but one that suffers from poor bioavailability. Implant
into the epididymal fat of lean mice indicates that resveratrol augments an antiinflammatory environment established by PLG scaffolds without drug. Furthermore, this
strategy protected against inflammatory stimuli, such as mice fed a high fat diet and
adipocytes treated with pro-inflammatory cytokines. Additionally, mice pre-treated with
resveratrol loaded scaffolds and then fed a high fat diet gained significantly less body
weight and adipose tissue mass compared to mice that received scaffolds without the drug.
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Collectively, this shows that PLG scaffolds are a promising platform for the treatment of
metabolic diseases.
Secondly, we characterize the impact of chemotherapy treatment on adipose tissue
remodeling as a model for cancer associated cachexia. Here we report for the first time that
a clinically relevant bolus of doxorubicin significantly reduces animal body weight and
induces fibrosis in subcutaneous adipose tissue in female rats. Similar to cachexic patients,
this response was associated with an increase in collagen 1 and a marker of activated
fibroblasts. Finally, we indicate that the subcutaneous adipose tissue exhibited greater
fibrosis compared to visceral adipose tissue. This work is expected to provide greater
understanding of doxorubicin’s potential role in promoting cancer-associated cachexia and
provide insight for the development of future strategies to sustain adipose tissue health
during chemotherapy treatment.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE

1.1 Obesity Epidemic
Obesity is a metabolic disease defined as excessive fat accumulation1. A patient is
clinically considered obese when his or her body mass index (BMI), calculated as weight
(kg) / height (m2), is greater than or equal to 30 and severely obese when his or her BMI is
greater than or equal to 402. The Center for Disease Control and Prevention’s recent report
states that 42.4% of U.S. adults (age 18 and older) are considered obese and 9.2% are
considered severely obese based on the previously stated definitions2. In 2000, the
prevalence of obesity and severe obesity in U.S. adults were 30.5% and 4.7%, respectively,
indicating a striking increase in the percent of both populations over the last two decades2.
Therefore, a significant portion of the U.S population deals with this disease and its
associated diseases, as obesity is a key risk factor for several chronic and life-threatening
diseases, including heart disease, stroke, type 2 diabetes, and cancer3. As the prevalence of
obese patients increase, it is likely that the prevalence of these comorbidities will increase
as well. Relevant to the current global public health crisis, obesity was determined to be a
risk factor for more severe outcomes during the influenza A H1N1 pandemic of 2009 and
therefore, is likely to also be a risk factor for COVID-194,5. In addition, not only does
obesity have a negative impact on patient quality of life in terms of mobility, productivity,
and mental state, but also has a significant economic impact as well. For example, the
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healthcare costs of obese patients are approximately 30% higher than patients with a
normal weight6. Furthermore, annual medical cost from treating obesity-related disorders
in the U.S. is projected to increase by $28 billion per year by 2020 and $66 billion per year
by 2030 due to the increase in prevalence of obesity and obesity related disorders6.
Collectively, continued increase in obesity prevalence and the disease’s overwhelming
health and economic burdens signify the need for continued research activities to further
our understanding of the biological events driving the disease and to develop novel
therapeutic platforms.
1.2 Adipose Tissue Function
Obesity is associated with excess accumulation of fat, or adipose tissue, which is
the main organ involved in the progression of this disease. This tissue functions as the
body’s main energy reservoir and plays a central role in maintaining whole body energy
homeostasis7. Adipocytes, the tissue’s parenchymal cell, accomplish this by storing excess
caloric energy in the form of triglycerides in specialized lipid droplets8. As other organs in
the body require energy, triglycerides are broken down into fatty acids, via a process called
lipolysis, released into the blood stream and are ultimately taken up by the energy
demanding organs9.
Decades of research indicate a key function of adipose tissue as a storage site for
lipids; however, in the last two decades, it has become well accepted that this tissue also
functions as an endocrine organ10. Indeed, the adipose tissue regulates metabolism,
immunity, reproduction, and many other processes required for homeostasis through the
hormones, cytokines, and other factors it secretes8,11,12. For example, the adipose tissue
modulates whole body metabolic systems through the release of adipokines from
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adipocytes which travel to distant organs via the blood stream to promote certain responses
critical to metabolic health. Commonly studied adipokine examples include adiponectin,
an adipokine involved in increasing glucose uptake and lipid metabolism13, and leptin,
which controls satiety10.
The adipocyte is not the only endocrine acting cell in the adipose tissue. In fact, the
adipose tissue is comprised of several other cell types, such as immune cells and
stromovascular cells, that secrete various factors that can signal in both an endocrine and
paracrine manner, impacting distant tissues as well as local adipocytes. Macrophages, an
innate immune cell, make up 5% of the total cells within the adipose tissue and is the largest
immune cell population residing within the tissue14. Under lean conditions, adipose tissue
resident macrophages possess an anti-inflammatory phenotype in which they produce antiinflammatory cytokines, lipid buffering, and promote insulin sensitivity15. In addition,
adipose tissue macrophages also play a key role in immune surveillance and removal of
dying cells via efferocytosis within the tissue14,16. Furthermore, macrophages and their
secreted factors control adipocyte metabolic function, including lipolysis and
differentiation16. For example, anti-inflammatory macrophages enhance mitochondrial
activity in adipocytes in vitro via both direct-contact and non-contact mechanisms,
suggesting the role of soluble factors17. Undoubtedly, adipose tissue function is
inextricably linked to the immune cells present within it and their phenotype. The following
section will further elaborate on the role macrophages play during obesity induced adipose
tissue dysfunction.
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1.3 Adipose Tissue Dysfunction During Metabolic Disease
Looking at lipid metabolism through the eyes of a chemical engineer, one should
imagine an energy balance, where the amount of energy taken into the system (i.e. eaten)
should balance with the amount of energy needed by the system to function (energy
expenditure). In the case of chronic overnutrition, there is a higher amount of energy going
into the body than what the body requires; therefore, this energy must be stored. Adipocytes
store this energy in the form of lipids in specialized droplets18. Therefore, during obesity,
lipid droplets become larger and in turn increase the size of the adipocytes, termed
hypertrophy. However, the adipose tissue has limited storage capacity; therefore, chronic
overnutrition can lead to an accumulation of lipid metabolites in other tissues, such as the
liver and skeletal muscle.
Lipid accumulation in the adipose tissue leads to local inflammation as the number
of macrophages are significantly increased in the adipose tissue during obesity, making up
to 40% of all adipose tissue cells in obese mice19. Environmental changes that occur in the
adipose tissue during obesity development, such as an increase in lipid exposure and
hypoxia, activates resident macrophages and adipocytes to secrete pro-inflammatory
chemokines and cytokines, such as monocyte chemoattractant protein-1 (MCP-1), TNF-α,
and IL-620. Pro-inflammatory cytokine signaling can significantly modulate adipocyte
metabolism. For example, TNF-α signaling leads to reduced glucose uptake, increased
lipolysis, and potentially reduced adipocyte differentiation and lipogenesis21. Through the
release of these soluble factors, the increase in the number of proinflammatory
macrophages in the tissue has been suggested to contribute to local and systemic insulin
resistance, potentially leading to a type 2 diabetic state21.
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1.4 Current Obesity Treatment Strategies
Current methods to mitigate this disease include lifestyle changes, pharmaceuticals,
and bariatric surgery. Each of these strategies pose challenges that hinder their
effectiveness. First, diet and exercise alone do not typically result in long term outcomes
for those with severe obesity. For example, severely obese patients who participated in a
dietary and physical activity intervention plan and group support sessions lost
approximately 9% of their body weight within the first year; however, these participants
gained almost half of their loss back by year four22.
There are several FDA approved medications that are prescribed to patients to be
taken in combination with lifestyle interventions as a weight loss regimen. Some of these
medications work to make patients feel satiated faster, such as Lorcaserin, and others work
to reduce the amount of fat absorbed after eating, such as Orlistat23. In fact, patients who
supplement their lifestyle intervention regimen with FDA approved weight loss drugs lose
3-9% more of their starting weight compared to those patients who do not24. However, the
severe side effects associated with these drugs, including increased heart rate and diarrhea
among several others, deters their use. Furthermore, in February 2020, the FDA requested
to withdrawal Lorcaserin from the market due to an increase in potential cancer risk21.
Therefore, these drugs are considered effective in achieving weight loss; however, their
negative effects likely out ways their benefits.
Finally, bariatric surgery, an option for the morbidly obese, is highly invasive and
comes with high risks of post-operative or chronic complications25. For example, sleeve
gastrectomy is a common bariatric surgery where the patient’s overall stomach size is
reduced by 25%. One in every 5 sleeve gastrectomy patients develop gastroesophageal
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reflux disease (GERD), which is associated with frequent and severe heartburn, vomiting,
and difficulty swallowing, leading to maladaptive eating and possible weight gain25. If
GERD does not improve naturally, medications are used to manage the severe symptoms26.
Due to the ineffectiveness and inconveniences of the current obesity management
strategies, it is quite evident that novel therapeutic strategies must be developed. These
strategies should be minimally invasive, prevent unwanted side effects associated with
systemically administered drugs and bariatric surgeries, and designed to also be combined
with diet and exercise.
1.5 Biomaterials for Tissue Engineering Applications
Tissue engineering is a sophisticated collaboration between engineering, life
sciences, pharmaceutical science, and material science. The primary goal of tissue
engineers is to use a combination of biocompatible materials, drugs, and biological
products, such as cells and proteins, to repair injured tissue or direct tissue function27.
Generally, biomaterials developed for these applications are designed to allow for cell
mobility and extracellular matrix deposition in order to enhance cell survival and integrate
the material with the host tissue28. Therefore, a common construct for tissue engineering
applications is in the form of porous scaffolds fabricated from either biological or synthetic
materials which can be loaded with drugs, proteins, cells, or a combination thereof to
promote desired tissue events29. Undoubtedly, one of the most commonly used synthetic
polymers for this application is poly(lactide-co-glycolide) (PLG), likely due to its
biocompatibility, biodegradability, and previous FDA approval30. One example of an FDA
approved PLG construct is Zoladex, a PLG matrix loaded with goserelin acetate that is
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used as a prostate cancer treatment31. A central focus of this dissertation is the use of porous
PLG scaffolds for adipose tissue engineering.
Polymer scaffolds have been successfully utilized as platforms for adipose tissue
engineering. For example, they have been supplemented with adipose derived stem cells,
immune cells, and/or a host of different stimuli to generate healthy adipose tissue in vivo
as a repair mechanism for soft tissue defects as well as to develop 3-dimensional in vitro
models to better study adipose tissue biology and potential obesity therapeutics in the
dish32–34. Furthermore, polymer scaffolds have extensively been used to enhance the
survival of endocrine cell (islets) grafts upon implant into the adipose tissue28,35–37.
However, to our knowledge, little efforts have been taken to use these devices to directly
repair injured adipose tissue or impact its inherent metabolic or endocrine functions.
Furthermore, little research has tested the benefit of these scaffolds as drug delivery
vehicles to directly target the adipose tissue. We propose that polymer scaffolds could be
a very convenient strategy to deliver promising anti-obesity drugs whose success may
otherwise be hindered by poor bioavailability or harsh side effects. Furthermore, while
scaffolds have been implanted into the adipose tissue previously, their effects on the
adipose tissue immune compartment and lipid metabolism remains uncharacterized.
1.6 Host Response to Biomaterial Implants
A central aim for tissue engineers is to understand the immune response to
biomaterial implants and develop strategies to mitigating or direct this response that ensues
upon implant of foreign materials. The immune response to biomaterial implants within
the adipose tissue remains largely uncharacterized; however, studies of subcutaneous
biomaterial implant indicates a cascade of events that make up an acute inflammatory
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phase, chronic inflammatory phase, and wound healing phase. Upon implant, injury
disrupts homeostasis within the tissue and the adsorption of proteins on the surface of the
material induces the acute inflammation phase38–40. During this phase, proinflammatory
cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) as well as
chemokines, such as CXCL1 and monocyte chemotactic protein 1 (MCP-1), are secreted
to recruit neutrophils and monocytes from the blood stream and into the implant site38–40.
If the material is not fully degraded during the acute phase, the chronic inflammation phase
follows and is characterized by the presence of macrophages, monocytes, lymphocytes,
such as natural killer (NK) cells, T cells, and B cells at the implant site38–40. The wound
healing process begins with the resolution of inflammation through the increase of antiinflammatory cytokines, such interleukin-10 (IL-10), interleukin-4 (IL-4) and interleukin13 (IL-13), downregulation of inflammatory mediators, and apoptosis of immune cells38–
40

. IL-4 and IL-13 stimulate macrophages to fuse together to form multinucleated giant

cells at the biomaterial interface38–40. Furthermore, anti-inflammatory macrophages
stimulate extracellular matrix remodeling and fibroblast activation resulting in the
encapsulation of the material38–40. In terms of developing implantable devices to modulate
adipose tissue function for the treatment of metabolic disease, it would be beneficial to
limit inflammatory cytokine production upon implant while simultaneously enhancing
anti-inflammatory cytokines that may improve adipose tissue health. This is particularly
important since excess adipose tissue inflammation characterized by inflammatory
immune cell infiltration and inflammatory cytokine production is associated with
metabolic disease progression.

8

1.7 Fundamentals of PLG Drug Delivery Devices
1.7.1 Fabrication of PLG Microparticles and Scaffolds
PLG is an attractive polymer to use in the development of drug delivery devices
due to its biodegradability, biocompatibility, and its easily tailored characteristics, such as
molecular weight and lactide:glycolide ratio (composition)

41

. In addition, it is easily

fabricated into drug delivery devices42. Extensively used PLG drug delivery constructs are
in the forms of microparticles and scaffolds41. Our work revolves around loading drugs
into PLG microparticles via a single emulsion (oil in water) solvent evaporation process43.
Briefly, PLG and drug of choice are dissolved in an organic solvent and then this mixture
is emulsified using a homogenizer in the presence of an emulsifier (such as polyvinyl
alcohol). This mixture is added to water in which the organic solvent is extracted thus
hardening the oil droplets into particles. The particles are washed and removed via
centrifugation and subsequent lyophilization. Certainly, one can directly inject these
particles for various applications, but in the case of our work, we then mix these particles
with a sacrificial porogen, salt, to form our porous drug loaded PLG scaffolds. Briefly, the
particle salt mixture is pelleted under a ton of pressure in a die of specific dimensions and
this pellet is then placed in a custom-made pressure vessel exposed to high-pressure CO2
gas. In this environment, the glass transition temperature of PLG is reduced, therefore
liquifying the polymer surrounding the salt crystals44. After a pressurization and
depressurization sequence, the particles return to a solid state fused around the salt
crystals44, which is leached from the scaffold after washing in deionized water leaving a
porous drug loaded matrix. Once fabricated, scaffolds are dissolved in an organic solvent
and measured against a standard curve using a spectrophotometer to determine initial drug
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loading. Furthermore, drug release kinetics are determined by incubating drug loaded
scaffolds in deionized water at 37 °C and 5% CO2 and then measuring the amount of drug
in the scaffold after certain time frames. Several polymer properties can be modified prior
to fabrication that will impact drug release from the scaffold. PLG degradation
fundamentals and how polymer properties alter degradation are further discussed in the
next section.
1.7.2 Factors that Effect Release Kinetics
PLG is deemed biodegradable as it degrades in water into lactic acid and glycolic
acid via hydrolysis of its ester linkages45. Degradation highly depends on bulk erosion such
that water penetrates the matrix and hydrolyzes the polymer into oligomers and then
monomers41. A biphasic drug release profile is commonly observed using PLG devices
where an initial burst of drug is followed by a stable release phase. The initial burst is due
to drug on the surface as well as initial penetration of water that begins to decrease the
molecular weight of the polymer, but has not hydrolyzed the polymer to the point of
monomer production41. In the second phase, drug diffuses through the polymer layer as
water hydrolizes the polymer into oligomers and monomers41. Polymer degradation can be
modified by altering polymer characteristics, such as composition, molecular weight, and
matrix size and geometry42. For example, degradation rate increases with the glycolic
portion of the polymer composition; therefore, a 65:35 lactic acid to glycolic acid ratio
degrades faster than a 75:25 ratio41. Furthermore, higher molecular weight polymers
generally exhibit slower degradation rates. Lastly, the size and shape of the matrix will
impact the surface area to volume ratio, which increases the degradation rate42. Therefore,
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PLG is a suitable material to achieve desired delivery kinetics of various drugs as the
degradation kinetics can be easily altered by changing polymer properties.
1.8 Resveratrol
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a naturally occurring polyphenol
found in various plants, such as grape skins and peanuts, that, in plants, protects the plant
against ultraviolet rays, pathogens, injury, and abiotic stresses46. Since the “French
paradox” was termed, a proposal that wine consumption protected French people from
heart disease despite their consumption of a high fat diet, resveratrol has established a
reputation of providing health benefits47. Relevant to our overall work, this molecule has
been extensively studied for its anti-inflammatory and anti-obesity properties48. For
example, cultured adipocytes treated with conditioned media from resveratrol and LPS
treated RAW 264.7 macrophages protected cells from elevated levels of TNF-α and IL-6
and inflammation-related changes in adipokine gene expression49.

In addition, oral

resveratrol treatment significantly reduced body weight and adipose tissue mass in high fat
diet fed and genetically obese rodents50–53. Much research indicates that resveratrol
enhances activity of proteins that lead to lipid mobility via lipolysis and lipid catabolism
via fatty acid oxidation54–59. For example, resveratrol has shown to increase the expression
of adipose triglyceride lipase (ATGL)52,54,55,60 and carnitine palmitoyl transferase 1
(CPT1)56–58,61, the rate limiting enzymes involved in lipolysis and fatty acid oxidation,
respectively18. Furthermore, these effects are likely a result of resveratrol activation of
AMP kinase (AMPK)54,59. Therefore, through its cellular actions in adipocytes and
macrophages, resveratrol has achieved pre-clinical success as an obesity therapeutic.
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However, resveratrol clinical trials have resulted in modest or no effects on
metabolic parameters in obese and type 2 diabetic patients62,63. A significant shortcoming
of resveratrol’s use as an anti-obesity drug that has hindered its clinical success is its poor
bioavailability64. When taken orally, sulfate conjugation occurs rapidly in the intestine and
liver, which appears to be the rate-limiting step in resveratrol’s bioavailability65. We
propose that resveratrol’s clinical effectiveness as an anti-obesity drug could be improved
by locally delivering the drug to the target tissue. Therefore, resveratrol is an appropriate
candidate for delivery via PLG scaffold directly to the adipose tissue in order to bypass this
rapid metabolism that occurs when the drug is taken orally.
1.9 Resveratrol Loaded Polymer Scaffolds for Adipose Tissue Engineering
A central hypothesis of this dissertation is that resveratrol loaded PLG scaffolds
promote favorable immune and metabolic responses upon implant into adipose tissue
compared to PLG scaffolds without a drug payload. A combination of animal and cell
culture studies are utilized in this project to understand how scaffold-based delivery of
resveratrol modulates the immune response to PLG scaffolds and enhances local lipid
metabolism after implant into adipose tissue. The results from this work aims to
demonstrate that this technology is a promising novel strategy for the treatment of obesity
and lays the foundation for future studies using biomaterials as a strategy to direct the
adipose tissue’s inherent endocrine and metabolic functions.
1.9.1 Aim 1: Characterize the immune response to resveratrol loaded poly(lactide-coglycolide) scaffolds after implant into adipose tissue
As biomaterial therapies are used to address adipose tissue dysfunction, the immune
response to these systems must be established. This is especially important as the immune
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compartment of adipose tissue can drive metabolic disease. Therefore, the first aim of this
work to test the hypothesis that resveratrol delivery from PLG scaffolds would limit
inflammation following implant into visceral adipose tissue compared to PLG scaffolds
without drug. In this aim, we established that PLG scaffolds implanted into adipose tissue
of healthy C57BL/6 mice promote an anti-inflammatory environment characterized by low
levels of pro-inflammatory cytokines compared to unmanipulated fat. Resveratrol delivery
augments this anti-inflammatory environment by decreasing monocyte and lymphocyte
numbers at the implant site and increasing expression of anti-inflammatory cytokines. To
investigate therapeutic relevancy, we investigated resveratrol delivery to induce an antiinflammatory response in proinflammatory environments such as adipocytes challenged
with TNF-α and the fat pads of mice challenged with a high fat diet. This aim results in the
conclusion that PLG scaffolds are a promising platform for the treatment of adipose tissue
inflammation that drives metabolic disease as the polymer alone induces an antiinflammatory environment and that it can be easily engineered to deliver drugs that can
further augment this response.
1.9.2 Aim 2: Assess the efficacy of resveratrol loaded scaffolds to enhance adipose tissue
lipid metabolism
As a strategy to overcome resveratrol’s poor bioavailability, resveratrol was
incorporated into the matrix of PLG scaffolds for direct delivery to the adipose tissue. The
second aim of this project assessed the ability of resveratrol loaded scaffolds to enhance
local lipid catabolism compared to scaffolds with no drug. Studies in this aim investigate
adipocyte size and expression of proteins involved in lipid catabolism after implant in lean
mice led to the proposal that resveratrol scaffolds decrease adipocyte size because
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resveratrol increases lipid utilization in scaffold-infiltrating immune cells, possibly through
elevating CPT1 levels or activity. Furthermore, mice pre-treated with resveratrol scaffolds
and then fed a high fat diet gained significantly less total body weight and epididymal
adipose tissue mass compared to mice that received scaffolds containing only polymer.
Importantly, this scaffold-based strategy required a single administration compared to
previous animal studies indicating that oral resveratrol delivery requires daily dosing. This
work indicates that localized delivery of metabolism modulating agents to the adipose
tissue may overcome issues with bioavailability and that the role of biomaterials should be
further investigated as a therapeutic strategy for metabolic disease.
1.10 Understanding Adipose Tissue Remodeling in Response to Chemotherapy
A key goal of this dissertation is to develop drug loaded scaffolds to protect adipose
tissue from inflammatory stimuli, such as high fat diet induced obesity. Like obesity,
another instance where adipose tissue inflammation may promote the disease is cachexia66.
Cachexia is a condition associated with involuntary adipose tissue atrophy resulting in
considerable weight loss that affects 50-80% of cancer patients67 and is responsible for
approximately 20% of cancer-related deaths68. This debilitating symptom of cancer
progression significantly reduces patient quality of life and correlate with worsened
prognosis68. This condition may be, in part, related to the use of chemotherapies, such as
doxorubicin, an extensively used chemotherapeutic agent for the treatment of a wide
variety of cancers69. Treatment with this chemotherapy is associated with toxicity of
various organs, including heart, kidneys, and liver, in addition to other severe and
unpleasant side effects70. Doxorubicin’s negative effect on adipose tissue function may
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play a role in cachexia development; however, only few studies have pre-clinically
characterized the impact of doxorubicin treatment on adipose tissue function71–73.
Biopsies from cachexic cancer patients have presented with subcutaneous adipose
tissue architectural remodeling, such as decreased adipocyte area, increased inflammatory
cell infiltration, and extracellular matrix deposition, all of which have significant negative
consequences to adipose tissue function and systemic processes controlled by this
tissue74,75. Studies have investigated doxorubicin’s impact on adipocyte lipid metabolism;
however, few studies have aimed to understand doxorubicin’s role in promoting adipose
tissue remodeling. Furthermore, there are several critical, unanswered questions that
should be addressed regarding the role of doxorubicin administered dose, dosing schedule
and the gender of the studied population in pre-clinical studies. Working to answer these
questions will provide greater understanding of doxorubicin’s potential role in promoting
cancer-associated cachexia and provide insight for the development of future strategies to
sustain adipose tissue health during chemotherapy treatment.
Aim 3: 1.10.1 Characterize the impact of a clinically relevant, chronic bolus of doxorubicin
on adipose tissue remodeling in female rats
To date, most in vivo work studying doxorubicin’s effect on adipose tissue has been
tested in male rodents by injecting approximately 2 mg/kg multiple times over several
weeks or once for few days71,73. However, this does not accurately model clinical dosages
of most cancer patients, which is approximately 20 mg/kg once every 3 weeks. In addition,
there is a significant need to study the effect in female rodents since doxorubicin is
regularly used to treat several female cancers, such as breast and ovarian cancer. Therefore,
the third aim of this project assessed the effect of a single, 20 mg/kg doxorubicin bolus on
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adipose tissue inflammation 9 days after injection, a time point 6 days longer than other
studies using this clinically relevant dose, in female rats. Body weight and fat pad weights
were assessed at the end of the study as a measure of administered doxorubicin induced
cachexia. Furthermore, remodeling was assessed by histological means, such as measuring
adipocyte area and number, as well as staining for extracellular matrix. A possible
mechanism of fibrosis was also developed. Visceral and subcutaneous adipose tissue
depots were analyzed to determine fat pad anatomical location as a factor involved in the
extensiveness of doxorubicin induced inflammation. This work results in a better
understanding of how doxorubicin effects visceral and subcutaneous adipose tissue
inflammation in female rats.
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CHAPTER 2
RESVERATROL DELIVERY FROM POROUS POLY(LACTIDE-COGLYCOLIDE) SCAFFOLDS PROMOTES AN ANTI-INFLAMMATORY
ENVIRONMENT WITHIN VISCERAL ADIPOSE TISSUE1
2.1 Introduction
While the adipose tissue is a common site for biomaterial supported delivery of
endocrine cells (i.e., islets), the field has yet to investigate biomaterial strategies to
modulate this tissue’s inherent endocrine function28,35–37,76. Indeed, the adipose tissue
regulates metabolism, immunity, reproduction, and many other processes required for
homeostasis through the factors it secretes8,11,12,77. Therefore, an ability to control adipose
secretory function is a promising avenue to treat metabolic diseases. In devising platforms
to modulate the adipose tissue, it is important to consider that (i) biomaterial implant causes
local changes in immune cell populations78 and (ii) adipose tissue function is inextricably
linked to the immune cells resident within it79,80. Furthermore, excessive adipose tissue
inflammation characterized by immune cell accumulation and inflammatory cytokine
production is associated with metabolic disease15,81,82. Thus, from a tissue engineering
perspective, it is important to understand how the adipose tissue immune environment

1

Murphy, K.P., Hendley, M.A., Isely, C., Annamalai, P., Pena, E., Gower, R.M. 2018.
ACS Applied Materials and Interfaces. 10 (50): 43363-43374. Reprinted here with
permission of publisher.
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responds to biomaterial implants and develop strategies to modulate this response, if
necessary.
The immune response to biomaterial implants within the adipose tissue remains
largely uncharacterized; however, studies of subcutaneous biomaterial implant indicates
there are three phases: acute inflammation, chronic inflammation, and wound healing78.
During the acute inflammation phase, proinflammatory cytokines such as tumor necrosis
factor-alpha (TNF-α) and interleukin-6 (IL-6), as well as chemokines, such as CXCL1 and
monocyte chemotactic protein 1 (MCP-1), are secreted to recruit neutrophils and
monocytes from the bloodstream and into the implant site40,78. Chronic inflammation
follows this phase and is characterized by the presence of macrophages, monocytes,
lymphocytes, such as natural killer (NK) cells, T cells, B cells, and foreign body giant cells
at the biomaterial interface40,78. The wound healing process begins with the resolution of
inflammation through the increase of anti-inflammatory cytokines, such as interleukin-10
(IL-10), interleukin-4 (IL-4), and interleukin-13 (IL-13), down regulation of inflammatory
mediators, and apoptosis of immune cells40. In terms of developing implantable devices to
modulate adipose tissue function, especially for treatment of metabolic diseases, it would
be beneficial to limit inflammatory cytokine expression upon device implant while
simultaneously enhancing anti-inflammatory cytokines that might improve adipose tissue
health.
In this study, we investigated resveratrol release from porous poly(lactide-coglycolide) (PLG) scaffolds that integrate with the adipose tissue28. Resveratrol, a naturally
occurring polyphenol, was selected because it protects mice and primates from diet induced
obesity, in part, through its metabolic effects on adipose tissue50,53,83–85. In addition,
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resveratrol decreases inflammation associated with biomaterial implant in bone, cartilage,
and the vasculature86–91. However, scaffold-based delivery of resveratrol to modulate the
immune response to biomaterial implant in the adipose tissue has not been investigated.
Therefore, we performed the following studies to investigate whether resveratrol delivery
from PLG scaffolds would limit inflammation and speed its resolution following implant
into visceral adipose tissue. We chose to deliver resveratrol directly from the scaffold
instead of oral delivery because resveratrol suffers from poor bioavailability and requires
frequent large doses to address adipose tissue inflammation50,53,65,83. To investigate
therapeutic efficacy of our strategy, we determined whether resveratrol delivery from
scaffolds could induce an anti-inflammatory response in proinflammatory environments
including adipocytes challenged with TNF-α and the fat pads of mice fed a high fat diet.
2.2 Materials and Methods
2.2.1 Particle Fabrication
Particles were produced by an oil-in-water emulsion-solvent evaporation
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma) and
ethanol (Sigma) containing 6% w/w PLG (purchased from Evonik, 75:25 mole ratio lactide
to glycolide, 0.76 dL/g) and 10 mg/mL of resveratrol (Sigma). The aqueous phase consisted
of 1% w/v PVA (Sigma) dissolved in ultrapure water. The oil phase was homogenized with
the aqueous phase using 1:7 volume ratio with a benchtop homogenizer. The emulsion was
then immediately added to ultrapure water and stirred for 5 hour to allow particles to harden
and organic solvents to evaporate. Particles were collected via centrifugation, washed with
ultrapure water, and lyophilized.
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2.2.2 Scaffold Fabrication
Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl particles
in a 1:30 ratio, and the mixture was then pelleted in a die. Scaffolds were gas-foamed using
800 psi CO2 at room temperature in a pressure vessel. The salt porogen was removed by
washing in ultrapure water. Complete salt removal was confirmed by scaffold weight and
microscopy. Scaffolds that did not contain resveratrol were fabricated from particles
produced using an oil phase that did not contain resveratrol or ethanol.
2.2.3 Scanning Electron Microscopy
Particles or scaffolds were added to carbon adhesive tape on aluminum stubs and
gold sputtered three times for 1 minute with a Denton Desk II vacuum sputter coater.
Compressed air was used to ensure a monolayer of particles prior to sputtering. Images
were taken on a TESCAN Vega3 scanning electron microscope at 10 kV.
2.2.4 Measuring Resveratrol Loading Capacity and Encapsulation Efficiency in PLG
particles and Scaffolds
Particles and scaffolds were weighed and then dissolved in a defined volume of
DMSO (Sigma) and analyzed for absorbance at 330 nm, which is the maximum absorbance
wavelength for these solutions as determined by a wavelength scan (Fig 2.1). PLG in the
solution did not affect resveratrol’s absorbance spectrum (data not shown). Absorbance
values were then compared to a nine-point standard curve allowing for the interpolation of
the unknown resveratrol concentration in the sample. Standard curves were highly
reproducible between experiments (Fig 2.2). Particle loading capacity (PLC) and scaffold
loading capacity (SLC) was determined using equations 1 and 2, respectively.
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MP−Recovered is the mass of particles recovered after particle fabrication, MRSV−Emulsion is
the mass of resveratrol added to the emulsion, and MP−Scaffold Fabrication is the mass of

particles used in scaffold fabrication.
2.2.5 3T3-L1 Cell Culture

3T3-L1 fibroblasts (ATCC) were differentiated into adipocytes following ATCC’s
protocol, with slight modifications. Briefly, 3T3-L1 cells were seeded in 6-well plates at
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80000 cells/well or 24-well plates at 20000 cells/well and cultured in DMEM (Corning
Cellgro) supplemented with 10% Super Calf Serum (GemCell) and 1% Pen/Strep (Fisher).
Forty-eight hours after confluence was reached, media was exchanged with differentiation
media consisting of DMEM supplemented with 10% FBS (Fisher), 10 µg/mL bovine
insulin (Sigma), 0.25 µM dexamethasone (Sigma), and 0.5 mM isobutylmethylxanthine
(Sigma). Forty-eight hours after differentiation media was added, media was exchanged
for DMEM supplemented with 10% FBS and 10 µg/mL bovine insulin. After another 48
hours, media was exchanged for DMEM supplemented with 10% FBS. Cells were then
cultured until treatment with particles or scaffolds, which occurred 9 days after exposure
to differentiation media.
2.2.6 Particle Treatment of 3T3-L1 Adipocytes and Oil Red O Assay
On day 9 of differentiation, 3T3-L1 adipocytes in 6 well plates were treated with
300 µg/mL of PLG particles, PLG+RSV particles 2 weeks after fabrication, or PLG+RSV
52 weeks after fabrication. As a positive control, 3T3-L1 adipocytes were treated with 60
µM resveratrol. Forty-eight hours later, cells were washed and then fixed using 10%
formalin in PBS. Immediately before the experiment, particles were washed in 35% ethanol
in water and then suspended in DMEM media.
An Oil Red O assay was performed on fixed cells to visualize their lipid content.
Cells were washed with ultrapure water followed by 60% isopropanol. Cells were then
incubated with Oil Red O (Sigma) for 10 min at room temperature followed by four washes
with ultrapure water to ensure removal of unbound Oil Red O. Images were taken on Nikon
Eclipse Ci microscope with a 4x objective. To quantify the staining, Oil Red O was
extracted from the cells by incubating them in 100% isopropanol for 10 min at room
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temperature. Absorbance of the isopropanol solution was then measured at 500 nm using
a spectrophotometer. Absorbance was normalized to that of untreated differentiated cells.
2.2.7 Resveratrol In Vitro Release Assay
To investigate resveratrol release, scaffolds were weighed and then incubated under
ultrapure water at 37 °C for 0.25, 1, 3, 7, or 14 days. At the end of the assay, scaffolds were
retrieved from the incubator and stored in a desiccator until dry. Dryness was confirmed
by scaffold weight. The amount of resveratrol remaining in the scaffold was then measured
as described in Section 2.2.4.
2.2.8 Animal Care and Scaffold Implant
All anima procedures were approved by the University of South Carolina
Institutional Animal Care and Use Committee. Six week-old male C57BL/6 mice were
purchased from Jackson Laboratories. Mice were allowed to acclimate for 2 weeks. Prior
to implant, all scaffolds were washed in 70% ethanol and then rinsed in sterile PBS. Mice
were anesthetized with isoflurane, and the surgical site was shaved and disinfected with
betadine and alcohol. Following a lower abdominal midline incision one scaffold was
wrapped into each epididymal fat pad (i.e., each mouse received two scaffolds). The
abdominal wall was then closed with a running stitch and the skin was closed with wound
clips. Epididymal fat pads were collected for analysis 3, 7, or 14 days after implant.
2.2.9 Flow Cytometry
Seven and 14 days after implants, epididymal fat pads were harvested following
euthanasia and washed in ice cold PBS (Sigma). Fat pads were minced, digested in
collagenase (Liberase TL, Roche), and passed through a 100 µm filter. The stromal
vascular fraction was harvested by centrifugation, washed in MACS buffer (PBS, 0.5 mM
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EDTA, 30% BSA) and incubated with anti-CD16/32 prior to adding an antibody cocktail
against extracellular antigens. The following antibodies were purchased from Biolegend:
anti-CD45 clone 30-F11, anti-Ly6G clone 1A8, anti-F4/80 clone BM8, anti-NK1.1 clone
PK136, anti-CD19 clone 6D5, anti-CD11b clone M1/70, anti-CD3 clone 17A2, and
Trustain fcX (anti-CD16/32) clone 93. The following isotype controls were also purchased
from Biolegend: mouse IgG2a clone MOPC-173, rat IgG2a clone RTK2758, rat IgG2b
clone RTK4530. After antibody incubation, cells were washed, fixed, and analyzed using
a FACS Aria flow cytometry (BD Biosciences). The number of CD45 cells in each flow
cytometry sample was calculated using Bang’s Laboratories Flow Cytometry Absolute
Count Standard, which was added prior to data acquisition. FlowJo software (Treestar) was
utilized to compensate and analyze data. FMOs with isotype controls were used to
determine specific antibody signal. The gating scheme used in the flow cytometry analysis
is depicted in Figure 2.3.
2.2.10 Enzyme Linked Immunosorbent Assay (ELISA)
Following euthanasia, epididymal fat pads were harvested at 3, 7, or 14 days after
scaffold implant, washed in ice cold PBS, frozen on dry ice, and stored at -80°C until
homogenization. Prior to homogenization, tissues were weighed and then homogenized in
a defined volume of RIPA buffer containing Halt Protease Inhibitor Cocktail (Thermo
Fisher Scientific), PhosStop (Sigma), and phenylmethylsulfonyl fluoride (PMSF) protease
inhibitor (Thermo Fisher Scientific) using a benchtop homogenizer. Insoluble materials
was removed by centrifugation. Whole tissue homogenate samples were aliquoted and
stored at -80°C until use.
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All cytokines were measured in whole tissue homogenate using Duoset ELISA kits
(R&D Systems); however, several modifications were made to the manufacturer’s
instructions to improve sensitivity. A high binding 96-well plate was incubated with
capture antibody overnight at 4°C. The plate was then blocked with 10% BSA for 3 hours
at room temperature. Samples were incubated on the plate overnight at 4°C. Detection
antibody incubation lasted for 3 hours at room temperature before incubation with
streptavidin-HRP for 2 hours at room temperature. After incubation with the substrate for
20 minutes, stop solution was added to stop the enzymatic reaction, and absorbance was
measured at 450 nm. Background was removed by measuring absorbance at 540 nm. A
standard curve was used to determine each cytokine concentration in each sample.
2.2.11 Western Blotting
Whole tissue homogenate was obtained as stated in the previous section. Total
protein in the sample was quantified using the Pierce BCA protein assay kit (Thermo Fisher
Scientific). 30-50 µg of protein was separated by 8-15% SDS polyacrylamide gel
electrophoresis, depending on targeted molecular weight, and transferred to 0.2 µm
nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in Trisbuffered saline containing Tween-20 (TBST) for 1 hour at room temperature. Primary
antibodies for Bax, Mcl-1, and IL-6 were purchased from Cell Signaling Technologies,
CD206 was purchased from Abcam, and arginase-1 was purchased from Santa Cruz
Biotechnology. Each primary antibody was added to each blot at 1:1000 dilution, with the
exception was arginase-1 which was added at 1:100 dilution, in 5% nonfat dry milk in
TBST overnight at 4°C. Each membrane was then washed with TBST before incubation
with a polyclonal secondary antibody (Abcam) or, in the case of arginase-1, a monoclonal
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secondary antibody (Biorad), conjugated to horseradish peroxidase for 1 hour at room
temperature. The blots were then developed with SuperSignal enhanced chemiluminescent
substrate solution (Pierce). To verify equal loading of samples, blots were incubated under
stripping buffer for 20 minutes and washed with TBST. The blot then underwent the same
protocol as previously stated to probe for GAPDH (Cell Signaling Technologies).
ImageLabs software was used to analyze the relative intensity of each protein.
2.2.12 High Fat Diet Feeding
Mice were allowed to acclimate for 2 weeks prior to being placed on a 60% high
fat diet (Research Diets D12492) while a control group was kept on a normal chow diet.
The high fat diet was initiated 1 week prior to scaffold implant, and the mice remained on
the diet until the end of the study. Five weeks after scaffold implantation, mice were
sacrificed under anesthesia, and epididymal fat pads were collected for analysis. Fat pads
were homogenized and analyzed for cytokine expression using ELISA.
2.2.13 In Vitro Model of 3T3-L1 Adipocyte Inflammation
On day 9 of differentiation, PLG or PLG+RSV scaffolds were introduced into wells
containing 3T3-L1 adipocytes. Prior to addition, all scaffolds were washed in 70% ethanol
and then rinsed in sterile PBS. After 72 hours of pretreatment with the scaffold, 10 ng/mL
TNF-α was then added to each well and allowed to incubate for an additional 24 hours.
Media was collected at this time point for further analysis. Differentiated cells not treated
with TNF-α served as a control. Cell media collected at the end of the experiment was
analyzed for MCP-1 using a Duoset ELISA kit (R&D Systems).
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2.2.14 Statistics
Comparisons between two or more groups over time were conducted with a twoway ANOVA followed by Tukey’s multiple comparisons test. The p-values calculated by
the two-way ANOVA which addresses the effect of resveratrol, time, and the interactions
between the two are reported as pdrug, ptime, and pinteraction, respectively. Comparisons
between three groups at a single time point were made with a one-way ANOVA followed
by Tukey’s multiple comparisons test. Comparisons between two groups at a single time
point were made with an unpaired t test. The number of samples analyzed and the statistical
analysis performed are detailed in each figure legend. All analyses were completed using
GraphPad Prism. In all figures, the error bars denote standard error of the mean (SEM).
2.3 Results
2.3.1 Characterization of Resveratrol Scaffolds
Resveratrol loaded PLG particles (PLG+RSV) were prepared using a single
emulsion and solvent evaporation technique. The morphology of these particles and
particles containing only the polymer (PLG) is shown in Figure 2.4 A-B. The images show
that the morphology of PLG+RSV particles are irregular in shape compared to PLG
particles, which are spherical. These particles were then used to fabricate scaffolds using a
gas foaming and particulate leaching method. The structure of PLG+RSV and PLG
scaffolds are shown in Figure 2.4 C-D. Both scaffolds contain a similar porous structure
indicating that particle morphology does not have an impact on scaffold structure. During
the gas foaming process, the polymer is saturated with high pressure CO2 (800 psi) which
leads to the nucleation and growth of gas pores in the polymer particles44. The polymer
particles expand and fuse around the salt particles, resulting in a continue matrix44. It is
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likely that the gas foaming process is the reason why particle morphology does not impact
the final scaffold structure.
The amount of resveratrol in particles and scaffolds was measured by dissolving
the polymer in DMSO and measuring the absorbance of the solution at 330 nm. Resveratrol
encapsulation within PLG particles is reproducible, with three representative batches
containing 54±2, 61±2, and 59±1 µg resveratrol/mg particles (Figure 2.5A). Scaffold
fabrication from these particles is also reproducible. After salt leaching, scaffolds made
from the particles in Figure 2.5A contained 35±1, 36±3, and 36±3 µg resveratrol/mg
scaffold (Figure 2.5B) and weighed 2.29±0.02, 2.48±0.17, and 2.43±0.07 mg (Figure
2.5C). The amount of resveratrol in a scaffold can be calculated by multiplying the loading
capacity by the scaffold weight, which was between 80 and 90 µg. Collectively, this data
demonstrates we can fabricate resveratrol loaded scaffolds with reproducible drug
payloads.
The drug encapsulation efficiency in the particles was 20.3 ± 0.7% (Table 2.1). This
encapsulation efficiency was impacted by the mass of PLG particles we were able to
recover following the single emulsion/solvent evaporation fabrication procedure. The mass
yield for particles was typically 40%. Drug loading capacity dropped from ~60 µg/mg for
particles to ~35 µg/mg for scaffolds, giving the scaffolds a drug encapsulation efficiency
of 59.6 ± 3.1% (Table 1). Inspection of our fabrication procedure suggests that resveratrol
is lost during the salt porogen removal step because scaffolds assayed immediately after
gas foaming have a drug encapsulation efficiency of nearly 100% (data not shown).
Resveratrol stability, which is indicated by its absorption at 330 nm92, was studied
by analyzing a fourth batch of particles and scaffolds shortly after fabrication and one year
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later (Figure 2.6 A-B). When particles were analyzed immediately after fabrication, they
contained 65 ± 0.5 µg resveratrol/mg particles and when this same batch of particles were
analyzed one year later, they contained 61 ± 6 µg resveratrol/mg particles (Figure 2.6A).
When scaffolds analyzed directly after fabrication, they contained 37 ± 0.6 µg
resveratrol/mg scaffold, and when scaffolds from the same batch were analyzed one year
later, they contained 36 ± 0.4 µg resveratrol/mg scaffold (Figure 2.6B). These results
indicate that resveratrol activity is not lost after one year when resveratrol particles or
scaffolds are kept in dry conditions and protected from light.
To confirm that resveratrol was active after one year of encapsulation in PLG, we
investigated the ability of PLG+RSV particles to induce lipolysis in differentiated 3T3-L1
adipocytes by measuring lipid content with an Oil Red O assay. We found that PLG+RSV
particles stored for either 2 or 52 weeks significantly decreased lipid content of the
adipocytes to a similar extent, while lipid content was not affected by the PLG particles
(Figure 2.6C). Representative microscopic images were used to validate the decrease in
lipid staining in the PLG+RSV and RSV treated groups (Figure 2.6D). Collectively, these
results demonstrate that resveratrol remains bioactive after its encapsulation in PLG and
that it remains active for at least one year.
The resveratrol release profile of scaffolds over 14 days was characterized in vitro
(Figure 2.7A). At each time point scaffolds were removed from the assay and tested for
resveratrol content. The initial amount of resveratrol in the scaffold was taken to be the
average amount of resveratrol measured in three scaffolds from the same batch
immediately after salt leaching. Resveratrol exhibited a biphasic release pattern (burst
followed by a plateau), with ~50% of the drug released in the first 3 days. The amount of
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resveratrol released during the plateau phase accounted for ~10% of the initial resveratrol
in the scaffold. The release profile indicated that there was ~30% of the resveratrol present
within the scaffold after 14 days. Importantly, this burst release of resveratrol could be
beneficial in decreasing the acute inflammatory phase which occurs 1-5 days after injury.
Minimal scaffold degradation (~5% mass loss) was required for drug release over this time
period (Figure 2.7B).
2.3.2 Effect of Resveratrol on Immune Cell Infiltration Following Scaffold Implant
To quantify the effect of resveratrol on immune cell infiltration into adipose tissue
following scaffold implant, we employed flow cytometry. Total immune cell numbers were
measured based on CD45 expression 7 and 14 days after implant (Figure 2.8A). As
expected, PLG scaffold implant increased immune cell numbers at day 7. Contrary to our
expectations, resveratrol did not decrease immune cell numbers at this time point relative
to PLG scaffolds. Surprisingly, immune cell numbers significantly decreased from day 7
to day 14 for both scaffold groups, and we could not detect differences between any of the
groups at day 14 by Tukey’s multiple comparison’s test. The data indicate immune cell
infiltration following PLG implant into fat largely resolves within 2 weeks without
intervention. While not significant, immune cell numbers in the PLG+RSV group tended
to be higher at day 7 and lower at day 14 compared to the PLG group.
To better understand these trends, 7 immune cell populations were measured at 7
and 14 days: macrophages (F4/80), neutrophils (Ly6G), monocytes (CD11b), NK cells
(NK1.1), T cells (CD3), NKT cells (NK1.1 CD3), and B cells (CD19) (Figure 2.8B-C).
For ease of interpretation, immune cell numbers for the scaffold groups are normalized by
the naïve controls. At day 7, resveratrol delivery resulted in a significant increase in
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neutrophils with a concomitant decrease in T cells, NK cells, and NKT cells (Figure 2.8B).
At 14 days, all populations exhibited a trend of decrease, but only monocytes, NK cells,
and B cell numbers were significantly lower in resveratrol groups (Figure 2.8C). The data
suggest that even though resveratrol dose not decrease the total number of immune cells,
it does have an impact on particular immune cell populations.
Flow cytometry revealed that macrophage number was not different between PLG
and PLG+RSV at either time point; however, we hypothesized that resveratrol may modify
macrophage phenotype. To identify changes in macrophage phenotype, two molecules
associated with M2 polarization, CD206 and arginase-193, were measured in scaffold
homogenates 7 days after implant using Western blot (Figure 2.9A).At this time point,
CD206 was unchanged in both the PLG and PLG+RSV scaffold groups compared to naïve
fat (Figure 2.9B). In contrast, arginase-1 was ~35 fold higher in both PLG and PLG+RSV
groups compared to naïve fat (Figure 2.9C). The data indicate that resveratrol delivery does
not impact CD206 or arginase-1 expression, but scaffold implant elevates arginase-1
expression above naïve levels.
2.3.3 Effect of Resveratrol on Cytokine Levels Following Scaffold Implant
Cytokines control immune cell infiltration, residence, and survival in the tissue.
Thus, we investigated the effect of resveratrol delivery on protein levels of
proinflammatory cytokines MCP-1, TNF-α, IL-6, and CXCL1 as well as anti-inflammatory
cytokines IL-4, IL-10, and IL-13 in whole tissue homogenates 3, 7, and 14 days after
scaffold implant. There was no significant interaction (pinteraction) between drug treatment
and time detected by two-way ANOVA for the analyses performed in Figure 2.10H. MCP1 exhibited the largest increase following PLG scaffold implant of all cytokines measured,
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but was not affected by resveratrol (Figure 2.10A). MCP-1 expression significantly
decreased by day 14 as determined by Tukey’s multiple comparisons test. Interestingly,
scaffold implant, irrespective of drug payload, did not increase whole tissue levels of TNFα, IL-6, or CXCL1 compared to naïve levels (Figure 2.10 B-D). We did detect a significant
effect of resveratrol on TNF-α (pdrug=0.0147) and CXCL1 (pdrug=0.0168) by two-way
ANOVA (Figure 2.10 H), but drug delivery largely served to bring expression up toward
naïve levels. To validate these findings, Western blot was used to detect IL-6 in all groups.
We were not able to detect IL-6 in any tissues by this method; however, IL-6 was detected
in Raw 264.7 cells after incubation with LPS and Brefeldin A (Figure 2.11).
In terms of anti-inflammatory cytokines, scaffolds, irrespective of drug payload,
did not modulate IL-4 expression (Figure 2.10E). On the other hand, there was a significant
effect of resveratrol on IL-10 (pdrug=0.0065) and IL-13 (pdrug=0.0023), with resveratrol
increasing expression of both these proteins. In addition, expression of both these
molecules increased over time (Figure 2.10F-G). Together, these results suggest that
resveratrol’s effect on IL-10 and IL-13 may be responsible for decreases in immune cell
numbers at day 14 as measured by flow cytometry (Figure 2.8B-C).
2.3.4 Effect of Resveratrol on Bax and Mcl-1 Following Scaffold Implant
Apoptosis is increased in tissues during resolution of inflammation, reflecting the
clearance of immune cells that are no longer needed40,94. In addition, resveratrol increases
immune cell apoptosis, especially in neutrophils95–102. Thus, we measured the expression
of Bax, a proapoptotic protein, and Mcl-1, an antiapoptotic protein, in whole tissue protein
homogenates 7 and 14 days after implant (Figure 2.12A). Bax and Mcl-1 proteins were
present in naïve fat (Figure 2.12A), but only Bax levels increased with scaffold implant
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(Figure 2.12A); Mcl-1 levels were largely unaffected (Figure 2.12B). There was no
significant interaction between treatment and time detected by two-way ANOVA for
Figure 2.12B or Figure 2.12C. There was a trend for resveratrol to increase Bax levels, but
it was not significant (pdrug=0.0508); however, over time Bax expression did decrease
(pdrug=0.0040). Collectively, these results suggest that scaffold implant into the fat may
increase rates of apoptosis since proapoptotic Bax increase and antiapoptotic Mcl-1 is
relatively unchanged; however, resveratrol’s ability to alter Bax expression, if indeed it
does, was difficult to detect.
2.3.5 Ability of Resveratrol to Induce Anti-Inflammatory Responses in Inflammatory
Environments
An important application of PLG+RSV scaffolds would be to induce an antiinflammatory response in inflamed adipose tissue. To investigate the ability of PLG+RSV
scaffolds to achieve this, we utilized a common model of adipose tissue inflammation in
which mice are fed a high fat diet. Mice received PLG or PLG+RSV scaffolds in both
epididymal fat pads 1 week after being fed a high fat diet. The mice were then fed the diet
for an additional 5 weeks prior to harvest of the epididymal fat (Figure 2.13A). Cytokine
analysis was conducted using ELISA to measure MCP-1, IL-10, and IL-13 in the
epididymal fat. High fat diet feeding resulted in an increase in proinflammatory cytokines
MCP-1 and a decrease in anti-inflammatory cytokines IL-10 and IL-13 (Figure 2.13B).
The results demonstrate that PLG+RSV scaffolds, but not PLG scaffolds, significantly
decreased MCP-1 expression in the epididymal fat. Interestingly, PLG+RSV scaffolds did
not increase the expression of IL-10 and IL-13.
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To investigate resveratrol’s anti-inflammatory effect on adipocytes, we utilized an
in vitro model of adipocyte inflammation. On day 9 after differentiation, cells were treated
with PLG scaffolds or PLG+RSV scaffolds for 72 hours and then treated with 10 ng/mL
TNF-α for 24 hours (Figure 2.13C). Media was collected and analyzed for MCP-1 using
ELISA. Differentiated cells that were treated with TNF-α secreted ~2.5 fold more MCP-1
compared to untreated differentiated cells (Figure 2.13D). PLG scaffolds had no effect on
MCP-1 secretion; however, PLG+RSV scaffolds significantly decreased MCP-1 compared
to differentiated cells treated with only TNF-α or pretreated with PLG scaffolds prior to
TNF-α treatment.
2.4 Discussion
This report presents the characterization of resveratrol loaded PLG scaffolds and
their novel use in modulating the immune response to biomaterial implants in the adipose
tissue. Porous PLG scaffolds containing resveratrol were fabricated using a gas
foaming/particulate leaching method in which NaCl served as the sacrificial porogen. To
our knowledge, this approach is not commonly used for the fabrication of small molecule
loaded PLG scaffolds, and our results provide further insight into drug loading and release
kinetics of this approach. Our scaffolds contained 37 µg of resveratrol per mg of PLG
(Figure 2.5), which is at least 4-fold higher loading than previous studies using
biodegradable polyester scaffolds to deliver resveratrol86,91. However, this scaffold
fabrication method was suboptimal because removal of the salt porogen led to a 40% loss
of resveratrol loaded in the scaffold. To improve drug loading efficiency of scaffolds, a
nonparticulate leaching method to promote scaffold porosity should be investigated.
Nonetheless, resveratrol loaded scaffolds fabricated using this method exhibited a burst
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and plateau release profile (Figure 2.7) and overall delivered a large amount of resveratrol
over 14 days compared to sintered resveratrol encapsulated PLG nanoparticles which
delivered 7 times less resveratrol in a sustained manner86. In addition, resveratrol in our
PLG scaffolds did not degrade over one year when stored at room temperature conditions
as determined by measuring absorbances at the wavelength of trans-resveratrol, the active
isomer of resveratrol103. Furthermore, we confirmed this finding with a bioactivity assay
that indicated both fresh PLG+RSV particles and those stored for one year induced
lipolysis in 3T3-L1 adipocytes and to the same extent (Figure 2.6). The ability to maintain
bioactivity while stored at room temperature is an advantage of small molecule delivery
compared to other immunomodulatory strategies that require temperature-controlled
storage. For example, proteins and viral vectors are kept at freezing temperatures to
maintain activity, posing challenged during manufacturing, storage, and transportation
once in the market.
Initially, in vivo studies investigated resveratrol delivery as a way to modulate the
immune environment within adipose tissue following implant of PLG scaffolds.
Resveratrol impacted the prevalence of monocytes and several lymphocyte populations
over the time course of our experiments (Figure 2.8). Monocytes and lymphocytes play
key roles in adipose tissue inflammation during obesity104; therefore, the ability to
modulate their number is significant to future therapies. Monocytes and lymphocytes are
recruited to sites of inflammation by inflammatory cytokines. Resveratrol delivery
increased expression of the anti-inflammatory cytokines IL-10 (Figure 2.10), which
inhibits inflammatory cytokine production and signaling in many cell types, and this effect
may be responsible for the decrease in monocytes and lymphocytes recruited to the scaffold
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implant site. IL-10 is produced by macrophages (among other cells), with M2 polarized
macrophages expression IL-10 at higher levels than proinflammatory macrophages105.
Thus, we hypothesized that resveratrol delivery increased macrophage polarization toward
an M2 phenotype within the implant site. Surprisingly, we were not able to detect elevation
of CD206 or arginase-1, markers of M2 macrophage polarization, following resveratrol
delivery (Figure 2.9). However, there was a 35-fold increase in arginase-1 due to the PLG
scaffold implant and it is likely that further upregulation via resveratrol was not possible
(Figure 2.9). In addition to IL-10, resveratrol delivery increased expression of IL-13
(Figure 2.10), which is not produced by macrophages, but by TH2 lymphocytes, mast cells,
basophils, eosinophils, and IL2 cells. In particular eosinophils and IL2 cells are present in
the adipose tissue and have the ability to shape immune responses favoring immune
resolution rather than inflammation106.
An ability to modulate the cytokine milieu in the adipose tissue would be useful for
treating metabolic diseases associated with adipose tissue inflammation. Therefore, we
investigated the efficacy of PLG+RSV scaffolds in mitigating adipose tissue inflammation
that occurs in high fat diet fed mice. We found that resveratrol delivery decreased
expression of MCP-1 in the adipose tissue of mice fed a high fat diet for 6 weeks (Figure
2.13). High fat diet elevates MCP-1 after 1 week107 and promotes inflammatory
macrophage infiltration into the adipose tissue, which drives systemic insulin resistance108.
Therefore, decreasing this cytokine is an important benchmark for treating adipose tissue
inflammation. We also found that pretreatment with PLG+RSV scaffolds prevented TNFα induced MCP-1 secretion from differentiated 3T3-L1 adipocytes (Figure 2.13),
suggesting that the decrease in MCP-1 in vivo was mediated, at least in part, by resveratrol
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acting on adipocytes. In contrast to healthy adipose tissue (Figure 2.9), PLG+RSV
scaffolds did not increase IL-10 and IL-13 expression in adipose tissue from mice fed the
high fat diet; however, scaffold implant did not further decrease the expression of these
anti-inflammatory proteins either, which were decreased by the high fat diet. Because
adipose tissue expression of IL-10 and IL-13 protects mice against the detrimental effects
of high fat diet109–111, future studies should aim to quantify small molecules that increase
these factors when released from scaffolds implanted into the adipose tissue.
We hypothesize that the potential mechanism for resveratrol’s protection against
MCP-1 elevation is through its effects on the NF-κB pathway, a regulator of cytokine
production. Resveratrol inhibits the DNA binding activity of the NF-κB complex through
activation of Sirt-1, which inhibits NF-κB transcription in 3T3-L1 adipocytes112.
Interestingly, upon degradation, PLG produces lactic acid, a bioactive molecule that
abrogates the proinflammatory response of macrophages stimulated with LPS via
downregulation of the NF-κB pathway through GPR82 receptor113,114. This is a plausible
mechanism as to why PLG scaffold without drug loading does not produce
proinflammatory cytokine production upon implant into adipose tissue (Figure 2.9).
Furthermore, delivery of lactate via PLG implant accelerates the wound healing
response115. Therefore, the delivery of resveratrol from a degrading PLG scaffold may
synergistically promote an anti-inflammatory environment through the combinatorial
actions of resveratrol and lactic acid on adipocytes and macrophages. Furthermore, PLG
degradation creates an acidic environment. Resveratrol is most stable at pH < 6116,117.
Therefore, this acidic environment could have beneficial effects on drug stability.
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Notable was our finding that PLG scaffold implant did not increase expression of
TNF-α and IL-6 in the epididymal adipose tissue relative to naïve fat, and in fact, these
cytokines appeared to decrease. Generally, the literature reports that biomaterial implant
increases these factors and an important metric for anti-inflammatory drug delivery is the
ability of the delivered factor to decrease their expression. However, we note from an
extensive literature search that rarely are the experimental groups receiving the “empty”
biomaterial and the “drug-loaded” biomaterial compared to an unmanipulated tissue37,118–
124

. Thus, in these cited studies it is possible that the “drug-loaded” group actually

decreased inflammatory gene expression below what we call “naïve” levels. On the other
hand, we may have uncovered an attribute specific to adipose tissue. In a healthy state, the
adipose tissue is biased toward anti-inflammation77; therefore, we hypothesize that upon
implant the biomaterial invokes a series of signaling pathways that downregulate
inflammatory mediators such as TNF-α and IL-6. In support of this hypothesis, we find
that scaffold implant upregulated arginase 35-fold (Figure 2.10), an enzyme that inhibits
production of TNF-α and IL-6125.
A limitation of the study is that we did not conduct a dose response. To minimize
animal use, we chose to deliver the maximal amount of resveratrol we could in a 2.5 mg
scaffold, which we knew from previous work is well tolerated by the mouse126. While
resveratrol ultimately had anti-inflammatory effects, the spike in neutrophils at the 7 day
time point that occurred with its delivery was likely counterproductive. As we believe the
neutrophil influx was the result of local resveratrol concentrations that were too high, future
studies should investigate not only scaffolds with lower payloads of resveratrol, but also
scaffolds with high payloads designed to release resveratrol more slowly.
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In conclusion, resveratrol can be encapsulated into PLG particles using a single
emulsion solvent evaporation technique and these particles can be formed into porous PLG
scaffolds using gas foaming followed by particulate leaching with NaCl as the sacrificial
porogen. This method results in scaffolds with high resveratrol loading and drug release
with a burst phase followed by plateau. In healthy tissue, resveratrol delivery augments an
anti-inflammatory environment established by PLG scaffolds, characterized by high
arginase-1 and low TNF-α and IL-6, through increased expression of IL-10 and IL-13. In
terms of therapeutic applications, PLG+RSV scaffolds decrease MCP-1 expression in the
fat of mice fed a high fat diet, an inflammatory molecule that spurs the chronic
inflammation associated with obesity’s comorbidities. Thus, we conclude that PLG
scaffolds are a promising platform for the treatment of adipose tissue inflammation that
drives metabolic disease, since the polymer alone induces an anti-inflammatory response
and the scaffold is easily engineered for drug and cell delivery. Finally, we hypothesize
that further investigation into the anti-inflammatory effects of PLG in the adipose tissue
will lead to new drug targets and therapeutic strategies for metabolic disease and other
syndromes associated with chronic inflammation.

2.5 Tables
Table 2.1: Resveratrol encapsulation efficiency for PLG particles and scaffolds.
Particles
Scaffolds

Drug Encapsulation Efficiency (%)
20.3 ± 0.7
59.6 ± 3.1
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2.6 Figures

Figure 2.1: Resveratrol wavelength scan. Wavelength scan for a solution containing
62.5 µg/ml resveratrol dissolved in DMSO containing 1 mg/ml PLG. The black dashed
line indicates the maximum is found at 330 nm.
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Figure 2.2: Resveratrol PLG standard curve reproducibility. A 9 point standard
curve for resveratrol was made using a solution of DMSO containing 1 mg/ml PLG.
The absorbance values were measured at 330 nm and then fit on a sigmoidal curve.
Particle and scaffold concentrations were interpolated using the standard curve. A-D
depict standard curves made during four independent experiments.
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Figure 2.3: Gating scheme for flow cytometry. Leukocytes were identified by CD45
expression. Cell aggregates were removed based on forward scatter and side scatter,
followed by side scatter width and height. For quantification of leukocytes of the
myeloid lineage, cells positive for Ly6G (neutrophils) were first identified. Cells
negative for Ly6G were identified and then gated for expression of F4/80
(macrophages). Cells negative for F4/80, but positive for CD11b were gates to exclude
expression of lymphocyte markers (CD3, NK1.1, and CD19) in order to identify
monocytes. For the quantification of leukocytes of the lymphocyte lineage, cells were
first based on their negative expression of myeloid markers (Ly6G, F4/80, and CD11b).
Cells negative for myeloid markers were then gates based on NK1.1 (natural killer cells)
and CD3 (T cells expression. Cells positive for both NK1.1 and CD3 were identified as
natural killer T cells. Finally, cells negative for NK1.1 and CD3 were gated based on
CD19 (B cells) expression.
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Figure 2.4: SEM images of resveratrol loaded PLG particles and scaffolds. (A-B)
Scanning electron microscope images of PLG+RSV (A) and PLG (B) particles. (C-D)
Scanning electron microscope images of scaffolds produced with PLG+RSV (C) and
PLG (D) particles.
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Figure 2.5: Resveratrol loading capacity of PLG particles and scaffolds. (A)
Resveratrol loading capacity of three representative batches of particles. Data is mean
± SEM from three independent measurements. (B) Resveratrol loading capacity of
scaffolds fabricated from the particles depicted in (A). Data is mean ± SEM from three
scaffolds. (C) Mass of scaffolds depicted in (B).
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Figure 2.6: Resveratrol loading capacity and activity after year long storage. (A)
Resveratrol loading capacity in a fourth batch of particles measured 2 and 52 weeks
after fabrication. Data is mean ± SEM from three independent measurements. (B)
Resveratrol loading capacity of scaffolds made from the particles in panel A measured
2 and 52 weeks after fabrication. Data is mean ± SEM from three scaffolds. (C) Lipid
content of differentiated 3T3-L1 adipocytes 48 hours after treatment with PLG particles,
PLG+RSV particles that were 2 or 52 weeks old, or free resveratrol (60 µM). Data is
from three independent experiments and shown as absorption normalized to
differentiated untreated 3T3-L1 adipocytes. Statistics conducted using a one-way
ANOVA followed by a Tukey’s multiple comparison’s test. * indicated p<0.05
compared to PLG. (D) Representative microscopic images of Oil Red O staining.
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Figure 2.7: Resveratrol release from PLG scaffolds. (A) Two-week in vitro release
profile of resveratrol loaded PLG scaffolds. (B) Scaffold degradation during the release
assay. Data is from 5 scaffolds per time point. Error bars denote SEM.
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Figure 2.8: Effect of resveratrol on immune cell infiltration following scaffold
implant. (A) Number of CD45 cells harvested from fat tissue following PLG and
PLG+RSV scaffold implant measured by flow cytometry. Statistics by two-way
ANOVA with a Tukey’s multiple comparison test. *indicates p<0.05 compared to naïve
at day 7. † indicates p<0.05 compared to the corresponding group at day 7. (B-C)
Immune cell numbers from tissue receiving PLG and PLG+RSV scaffolds normalized
to naïve numbers at (B) 7 and (C) 14 days after implant. Statistics calculated using a ttest, *indicates p<0.05 between PLG and PLG+RSV. N=8-9 scaffolds per treatment per
time point.
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Figure 2.9: Effect of resveratrol on expression of proteins associated with M2
macrophage polarization. (A) Representative blot of CD206 and arginase-1 protein
expression in adipose homogenates collected 7 days after scaffold implant. Naïve fat is
included for references. (B-C) Quantification of (B) CD206 and (C) arginase-1
expression from 6 mice per group. Statistics were determined using an unpaired t-test.

48

Figure 2.10: Effect of resveratrol on cytokine levels following scaffold implant. (A)
MCP-1, (B) TNF-α, (C) IL-6, (D) CXCL1, (E) IL-4, (F) IL-10, and (G) IL-13 were
detected by ELISA in scaffold homogenate collected 3, 7, and 14 days after scaffold
implant. Data is from 3-4 mice per condition. (H) Table of p values determined by a
two-way ANMOVA. * indicates p<0.05 compared to corresponding group at D7 and
D14 determined by Tukey’s multiple comparison.
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Figure 2.11: Detection of IL-6 in scaffold environment using western blot. (A)
Representative western blot of IL-6 (24 kDa) expression in whole tissue homogenate 3
days after implant. N=3 for naïve, PLG, and PLG+RSV groups. GAPDH served as
loading control. (B) Representative western blot of IL-6 expression in RAW 264.7 cells
after incubation with LPS and Brefeldin A (PC) and PLG homogenate 3 days after
implant.
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Figure 2.12: Effect of resveratrol on Bax and Mcl-1 following scaffold implant. (A)
A representative blot of Bax and Mcl-1 protein expression in adipose homogenates
collected 7 or 14 days after scaffold implant. Naïve fat is included for reference. (B-C)
Quantification of (B) Bax and (C) Mcl-1 expression from 7 mice per group. (D) A table
of the p values determined by a two-way ANOVA.
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Figure 2.13: Ability of resveratrol to induce anti-inflammatory response in proinflammatory environments. (A) Timeline of experiment for panel B. (B) MCP-1, IL10, and IL-13 detected by ELISA in adipose homogenate 5 weeks after scaffold implant
in mice fed a high fat diet. Data is from 3-4 mice per group. Statistics determined by
one-way ANOVA with a Tukey multiple comparison test. * indicates p<0.05 compared
to HFD. (C) Timeline of experiment for panel D. (D) MCP-1 was detected by ELISA
in media from 3T3-L1 adipocytes treated with scaffolds prior to treatment with TNF-α.
N=4 per group. Statistics determined by one-way ANOVA with a Tukey multiple
comparison test. * and # indicates p<0.05 compared to no scaffold and PLG,
respectively.
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CHAPTER 3
MODULATION OF ADIPOCYTE SIZE AND FAT PAD WEIGHT VIA
RESVERATROL RELEASING SCAFFOLDS IMPLANTED INTO THE
EPIDIDYMAL ADIPOSE TISSUE2
3.1 Introduction
The adipose tissue functions as the body’s main energy reservoir and plays a central
role in maintaining whole body energy homeostasis77. Adipocytes, the tissue’s
parenchymal cell, accomplish this by storing excess lipids in the form of triglycerides in
specialized lipid droplets8. As other organs in the body require energy, triglycerides are
broken down into fatty acids (via lipolysis), released into the bloodstream and are
ultimately taken up by the energy demanding organ127. However, the adipose tissue has a
limited storage capacity; therefore, chronic overnutrition can lead to an accumulation of
lipid metabolites in other tissues128,129. Furthermore, lipid accumulation in the adipose
tissue has significant consequences including adipose tissue inflammation and
dysregulated insulin signaling, which are associated with metabolic diseases such as
obesity and type 2 diabetes129,130.
Current methods to mitigate this lipid accumulation include lifestyle changes,
pharmaceuticals, and bariatric surgery131. Each of these strategies pose challenges that

2
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hinder their effectiveness. Diet and exercise alone do not typically result in long term
outcomes for those with severe obesity22 and FDA approved drugs that improve lipid
storage in the adipose tissues, for example thiazolidinediones, are complicated by off-target
effects including cardiotoxicity132,133. Finally, bariatric surgery is highly invasive and
comes with high risks of post-operative or chronic complications25. Therefore, a strategy
that enhances lipid metabolism in the adipose tissue and prevents the side effects associated
with systemically administered drugs that can also be combined with diet and exercise
would be highly beneficial to combat lipid accumulation.
Biomaterials have been extensively studied to repair injured skin, bone, and muscle;
however, only in recent years have researchers addressed adipose tissue with tissue
engineering strategies35–37,76,134. Our recent studies indicate that, upon implant into the
epididymal adipose tissue, scaffolds made from poly(lactide-co-glycolide) (PLG) initiate
remodeling of the host tissue that shares many characteristics of wound healing, including
recruitment of immune cells and extracellular matrix deposition134. This remodeling serves
to degrade and integrate the scaffold with the host tissue. To our knowledge, no one has
studied the metabolic consequences on the adipose tissue after biomaterial implant;
however, we anticipate that this response is energetically demanding, and fueled, in part,
by the metabolism of lipids135,136. In fact, our previously published results indicate that the
host response to PLG scaffolds is responsible for enhancing local lipid utilization as
evidenced by a decrease in epididymal fat weight in both healthy mice and mice challenged
with a high fat diet134.
In the current study, we investigated the hypothesis that the scaffold’s effects on
local lipid levels could be enhanced through the incorporation of resveratrol into the
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scaffold polymer matrix. Resveratrol, a natural polyphenol, was chosen because it
enhances activity of proteins that lead to lipid mobility via lipolysis52,54,55,60 and lipid
catabolism via fatty acid oxidation56–58,61. For example, resveratrol has shown to increase
the expression of adipose triglyceride lipase (ATGL), and carnitine palmitoyltransferase
(CPT1), the rate limiting enzymes involved in lipolysis and fatty acid oxidation,
respectively. In addition, the literature indicates that these effects are a result of
resveratrol’s activation of AMP kinase (AMPK)54,59. AMPK activation has shown to
regulate ATGL expression137 and inhibit acetyl-coA-carboxylase (ACC) leading to an
increase in CPT1 activity138.
To study resveratrol scaffold’s effect, we first characterized the tissue remodeling
induced by resveratrol loaded PLG scaffolds after implant into the epididymal adipose
tissue. We hypothesized that resveratrol’s impact on metabolic programs would decrease
lipid accumulation, as observed by adipocyte area, compared to PLG implants without a
drug payload 28 days after implant, a time point 2 weeks longer than our previously
published report134. Specifically, we measured resveratrol’s effect on the expression of
ATGL and CPT1 as well as AMPK activation. Furthermore, to study the ability of
resveratrol loaded scaffolds to prevent onset of high fat diet induced weight gain, mice
received either PLG scaffolds without a drug payload or resveratrol loaded PLG scaffolds
and were then challenged with a high fat diet containing 60% calories from fat, a mouse
model of diet induced obesity139. The epididymal fat pad was chosen as the implant site
because this fat pad expands more during the initial stages of high fat diet feeding compared
to other fat depots140; therefore, decreasing this fat pad’s mass would be a significant
achievement during the study time frame. While scaffolds have been used to deliver
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resveratrol to modulate inflammation for several tissue engineering applications86–89,91,141,
we are the first to investigate scaffold-based delivery of resveratrol to modulate metabolic
programs in the adipose tissue.
3.2 Materials and Methods
3.2.1 Scaffold Fabrication
Scaffolds were fabricated from PLG microparticles using a gas foaming, particulate
leaching technique. Particles containing resveratrol (Sigma) were fabricated as previously
described142. Briefly, a 1:3 volume ratio of dichloromethane (Sigma) and ethanol (Sigma)
containing 6% w/w PLG (75:25 mol ratio lactide to glycolide 0.76 dL/g, Evonik) and 10
mg/mL resveratrol was added to an aqueous solution of 1% w/v PVA (Sigma) in a 1:7
volume ratio and homogenized. The emulsion was then added to ultrapure water and stirred
for 5 hours to remove the dichloromethane and promote solidification of the polymer and
encapsulation of resveratrol. Particles were washed with ultrapure water and collected via
centrifugation. Particles were lyophilized and stored in aluminum foil in a desiccator to
ensure particles were protected from light and moisture. Particles that did not contain
resveratrol were fabricated in a similar fashion except the oil phase contained only
dichloromethane and 6% w/w PLG.
To fabricated scaffolds, polymer particles were mixed with a sacrificial porogen,
NaCl (250-500 µm particles), in a 1:30 mass ratio and pelleted in a die. The resulting tablet
was gas foamed using 800 psi CO2 at room temperature in a custom-made pressure vessel
and the salt porogen was removed by washing in ultrapure water. Complete salt removal
was verified by scaffold weight and microscopy. Scaffolds containing resveratrol were
made with resveratrol loaded PLG particles and scaffolds that did not contain the drug were
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made with particles containing only PLG. Scaffolds were fabricated so that they weighed
2.08 mg ± 0.06 mg (mean ± SEM). From here on, scaffolds that contain resveratrol are
referred to as “RSV scaffolds” and scaffolds containing only the polymer are referred to as
“PLG scaffolds.”
3.2.2 Characterizing Scaffold Structure and Pore Size
Scaffolds were added to carbon adhesive tape on aluminum stubs and gold
sputtered two times for 1 minute using a Denton Desk II vacuum sputter coater. Images
were taken on a Tescan Vega3 scanning electron microscopy at 5kV. The face of the
scaffolds was imaged to give a top view observation. Scaffolds were also imaged using a
Nikon Eclipse Ci microscope at 4x magnification. ImageJ was used to quantify the average
pore diameter in both scaffold groups.
3.2.3 Measuring Resveratrol Loading in Scaffolds
Resveratrol loading in scaffolds was measured as previously described142. Briefly,
after leaching, scaffolds were weighed and dissolved in a defined volume of DMSO
(Sigma). The solution was then analyzed for absorbance at 330 nm and absorbance values
were compared to a nine-point standard curve allowing for the interpolation of the
unknown resveratrol concentration in the sample. Scaffold loading was calculated as the
amount of resveratrol measured in the scaffold (µg) normalized by the mass of the scaffold
analyzed (mg).
3.2.4 In Vitro Release Assay
Resveratrol release from scaffolds over time was determined as previously
described. Briefly, scaffolds were weighed and incubated in ultrapure water at 37 °C for
0.25, 1, 3, or 7 days. At each time point, scaffolds were removed from the incubator and
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stored in a desiccator until dry, which was confirmed by scaffold weight. The amount of
resveratrol remaining in the scaffold was measured as described in the previous section.
3.2.5 Animal Care and Scaffold Implant
All animal procedures were approved by the University of South Carolina
Institutional Animal Care and Use Committee and NIH guidelines for the care and use of
laboratory animals were observed. Six-week-old male C57BL/6 mice were purchased from
the Jackson Laboratory and, upon arrival, acclimated for 2 weeks prior to the scaffold
implant procedure. Prior to implant, scaffolds were washed in 70% ethanol and rinsed in
sterile PBS. Mice were anesthetized with isoflurane and their abdomens were shaved and
prepped with betadine and ethanol. A lower abdominal midline incision was made, and one
scaffold was wrapped into each epididymal fat pad (i.e. each mouse received two PLG or
RSV scaffolds, one in each epididymal fat pad). The intraperitoneal cavity was closed with
a running stitch and the skin was closed with wound clips.
3.2.6 Animal Study Design
To investigate the effect of RSV scaffolds on adipocyte size and adipose tissue gene
expression, three mice per group (RSV or PLG) received a scaffold into each epididymal
fat pad and were then euthanized 28 days later. One fat pad was frozen for western blot,
and one fat pad was fixed and embedded in paraffin for histology. In a second study
designed to investigate adipose tissue gene expression at an earlier time point, 4 mice per
group were implanted with one scaffold per epididymal fat pad. Fourteen-days later mice
were euthanized and epididymal fat pads were harvested and frozen for western blot.
To assess the effect of RSV scaffolds on mice fed a high fat diet, five mice per
group (RSV or PLG) received a scaffold into each epididymal fat pad. Twenty-eight days
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after scaffold implant, mice were placed on a 60% high fat diet (Research Diets D12492)
and euthanized 28 days after induction of the diet. Fat pads were collected for protein and
histological analysis. Mice were allowed access to the diet ad libitum during the entire
study except when they were fasted prior to body weight measurements.
3.2.7 Fasting Weight Measurements
On days 14 and 28 after initiation of the high fat diet, mice were fasted for 6 hours
beginning at 7AM with access to water. Weight measurements were obtained by placing
the mouse into a beaker tared on an Ohaus digital scale.
3.2.8 Histological Analysis
After collection, fat pads were washed in sterile PBS, placed in 4%
paraformaldehyde for 24 hours, and then paraffin embedded. Serial, 5 µm sections were
cut from the paraffin blocks and stained with hematoxylin and eosin (VWR). Sections were
imaged using a Nikon Eclipse Ci microscope at 4x or 40x magnifications. ImageJ software
was used to quantify adipocyte area from 3 random 40x images per section. Three sections
were quantified from 3 mice per group. All adipocytes within the field of view were
quantified.
3.2.8 Western Blotting
Collected fat pads were washed in sterile PBS, frozen on dry ice and stored at 80°C. Tissues were homogenized in a defined volume of RIPA buffer (Fisher Scientific)
containing Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific), PhosStop (Sigma),
and PMSF (Thermo Fisher Scientific) using a benchtop homogenizer. Insoluble material
was removed by centrifugation and whole tissue homogenate samples were aliquoted and
stored at -80°C until use.
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Total protein in the homogenate was quantified using the Pierce BCA protein assay
kit (Thermo Fisher Scientific). Twenty or 30 µg protein was separated by 8 or 10%
polyacrylamide gel electrophoresis based on target protein molecular weight. Separated
proteins were then transferred to 0.2 µm nitrocellulose membranes. The membranes were
blocked with 5% nonfat dry milk in Tris-buffered saline containing Tween-20 (TBST) for
1 hour at room temperature. Primary antibody for phosphorylated AMPK-T172 (Cell
Signaling Technologies, CST), ATGL (CST), phosphorylated ACC-S79 (CST), and CPT1
(Abcam) was added to each blot at 1:1000 dilution in 5% BSA in TBST and allowed to
incubate overnight at 4°C before incubation with a polyclonal secondary antibody
conjugated to horseradish peroxidase (Abcam) for 1 hour at room temperature. The blots
were then developed with SuperSignal enhanced chemiluminescent substrate solution
(Thermo Fisher Scientific). To verify equal loading, blots were incubated with stripping
buffer for 25 minutes and washed with TBST. The blot then underwent the same protocol
as previously stated for total AMPK, total ACC, or GAPDH (all purchased from CST).
Blots probed for AMPK were stripped a second time and underwent the same protocol to
probe for GAPDH. ImageLabs software was used to analyze the relative intensity of each
protein.
3.2.9 Immunohistochemical Staining
Serial tissue sections from each mouse, 5 µm in thickness, were deparaffinized,
rehydrated, and processed for antigen retrieval in citrate buffer using a vegetable steamer.
Sections were blocked with a TBS solution containing Tween-20, BSA, goat serum, and
anti-CD16/32 (Biolegend) and incubated with an anti-CPT1 antibody (Abcam). Sections
were treated with hydrogen peroxide prior to incubation with an HRP labelled polymer
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conjugated to goat anti-rabbit immunoglobulins (EnVision+, Dako). HRP was detected
using the Liquid DAB+ Substrate Chromogen system (Dako). Mayer's hematoxylin (Dako)
was used to counterstain. Three sections from each mouse were stained and then imaged
using a Nikon Eclipse Ci microscope. Analysis included 3 mice per group.
3.2.10 Raw 264.7 Cell Culture and Resveratrol Treatment
Raw 264.7 macrophages (ATCC) were cultured at 37°C with 5% CO2 in DMEM
media (Fisher Scientific) supplemented with 1 mM sodium pyruvate (Fisher Scientific),
1500 mg/L sodium bicarbonate (VWR), 10% fetal bovine serum (Fisher Scientific), and
1% penicillin/streptomycin (Fisher Scientific) at 57,000 cells/cm2 in 6 well plates. Twentyfour hours after seeding, cells were treated with 0, 10 or 25 µM resveratrol dissolved in
ethanol. Twenty-four hours later, cells were removed via trypsin 0.25% EDTA (Fisher
Scientific) and a cell scraper. Cells were lysed in RIPA buffer supplemented with protease
inhibitors via 21G needle and syringe. Protein fraction was collected after centrifugation
at 10,000 xg for 10 minutes and stored in -20 °C. Western blot analysis of CPT1 in treated
macrophages was conducted as previously stated using 10 µg of total protein content which
was determined via BCA assay and β-actin (Sigma) served as the loading control.
3.2.11 Statistical Analysis
Statistically significant differences between PLG and RSV implanted groups were
evaluated using an unpaired student’s t-test. Statistically significant differences between
three groups were determined using a one-way ANOVA with a Tukey’s multiple
comparison test. Statistical significance was set to a p value less than 0.05. The number of
samples analyzed is detailed in each figure legend. All analyses were completed using
GraphPad Prism. In all figures, data indicates mean ± standard error of the mean (SEM).

61

3.3 Results
3.3.1 Resveratrol Scaffold Characterization
Scaffold structure was observed using scanning electron microscopy and light
microscopy and these images, shown in Figure 3.1 A-D, indicate that both scaffolds
contained similar porous structure. Indeed, ImageJ analysis of light microscopy images, as
representatively shown in Figure 1 B and D, determined the average pore diameter was
454±31.8 µm and 434±7.45 µm in PLG and RSV scaffolds, respectively, and therefore,
were not significantly different (Figure 3.1E). Resveratrol scaffolds used in this study
contained approximately 48±2 µg RSV/mg scaffold; therefore, delivering approximately
100 µg resveratrol total per 5mm x 2mm scaffold (Figure 3.1F-G). Release kinetics of
resveratrol from scaffolds used in this study is depicted in Figure 3.2. One-week in vitro
release characterization indicates a burst release profile where approximately 50% of the
resveratrol initially loaded in the scaffold is released in the first 3 days with approximately
30% of the initial resveratrol remaining in the scaffold after 7 days.
3.3.2 Adipose Tissue Composition after Scaffold Implant
Tissue sections from epididymal fat 28 days after PLG or RSV scaffold implant
revealed extensive cellular infiltration and protein deposition not present in unmanipulated
fat (Figure 3.3A,D, unmanipulated fat not shown). This tissue remodeling was localized
around irregular shape voids indicating pieces of scaffold removed during histological
processing (Figure 3.3 B,E; specific areas highlighted by black boxes in Figure 3.3 A,D).
There were no obvious qualitative differences in tissue remodeling as indicated by H&E
staining. Interestingly, however, from a metabolic perspective, adipocytes surrounding
RSV scaffolds looked to be smaller in area compared to those surrounding PLG scaffolds
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(Figure 3.3 C,F; specific areas highlighted by black boxes in Figure 3.3 A,D). Indeed,
quantification of all adipocytes surrounding RSV scaffolds were approximately 1000 µm2
compared to those surrounding PLG scaffolds which measured approximately 1500 µm2
(Figure 3.3G). Taken together, scaffolds induce local tissue remodeling in the adipose
tissue, while resveratrol delivery from scaffolds decreases adipocyte area compared to
scaffolds with no drug payload.
3.3.3 Expression of Key Proteins Involved in Lipid Metabolism Following Scaffold Implant
To further investigate a possible mechanism for resveratrol’s significant impact on
adipocyte area, proteins involved in lipid regulation were measured via western blot in
whole

tissue

homogenate.

Adipose

triglyceride

lipase

(ATGL),

carnitine

palmitoyltransferase 1 (CPT1), phosphorylated acetyl-co-A-carboxylase (pACC), and
phosphorylated AMP kinase (pAMPK) levels were quantified (Figure 3.4). Interestingly,
we did not observe a significant difference in the expression of these proteins between
scaffold groups at the 28-day timepoint. In addition, a large amount of variability was
observed when pACC and ACC were measured. We then looked at protein expression 14
days after implant to determine if any differences were present at an earlier time point.
Interestingly, at 14 days after scaffold implant, phosphorylated AMPK levels were
significantly higher in the RSV scaffold group compared to PLG (Figure 3.5E).
Since CPT1 is the rate limiting enzyme involved in fatty acid oxidation, we were
interested in how its spatial distribution was altered after RSV scaffold implant; therefore,
we stained fat pads collected 28 days after implant with CPT1 using immunohistochemistry
(Figure 6). We found that CPT1 was most highly expressed in the new tissue surrounding
both scaffolds (Figure 3.6A,B). Looking more closely at the scaffold environment
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indicated by black boxes, there is evidence indicating that CPT1 is expressed by the giant
cells, which are formed following macrophage fusion143, located at the interface of the
tissue and material (highlighted by yellow arrows), as well as other non-adipocyte cells in
the new tissue (highlighted by red arrows) (Figure 3.6C,D).
3.3.4 Expression of CPT1 in Resveratrol Treated RAW 264.7 Macrophages
The histology presented above indicated that macrophages in the scaffold
environment are CPT1 positive; however, we did not detect an effect of resveratrol on
CPT1 expression using westerns, which was surprising. It is possible that carrying out the
measurements in whole tissue homogenates kept us from detecting changes that were
occurring in the scaffold recruited cells. To determine if it is possible for resveratrol to
modulate CPT1 levels in macrophages, we treated RAW 264.7 macrophages with
resveratrol and measured CPT1 protein levels via western blot (Figure 3.7A,B). Twentyfour hours after initial seeding, the macrophages were treated with 10 or 25 µM resveratrol
for 24 hours. Western blot indicated that 25 µM resveratrol increased CPT1 expression by
30% relative to vehicle control (Figure 3.7B). No difference was detected between cells
treated with 10 µM and untreated cells indicating the importance of dose.
3.3.5 Protective Effect of Resveratrol Scaffolds in Mice Challenged with a High Fat Diet
To determine if resveratrol loaded scaffolds could prevent diet induced obesity
compared to PLG scaffolds, lean mice were pre-treated with RSV scaffolds for 4 weeks
prior to being placed on a high fat diet for an additional 4 weeks, as illustrated in Figure
3.8A. Body weight measurements indicate that 14 days after switching to the high fat diet,
mice that received RSV scaffolds gained significantly less weight than mice that received
PLG scaffolds (Figure 3.8B). This effect remained after 28 days on the high fat diet (Figure
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3.8B). Additionally, at the end of the study, epididymal fat pads collected from mice that
received RSV scaffolds weighed significantly less than those from the PLG scaffold group
(Figure 3.8C).
Histological sections of the epididymal fat pad collected at the end of this study
were analyzed similarly to those in the previously discussed in the lean animal study.
Adipocytes in the RSV scaffold group appeared smaller than those from the PLG scaffold
group (Figure 3.9A) and, indeed, image analysis supported this observation. In fact,
adipocyte area in the RSV scaffold group was 30% smaller compared to the PLG group
(Figure 3.9B). Similar to results observed in the lean animal study, this observation was
not accompanied by whole tissue modifications in ATGL, CPT1, pACC, or pAMPK in the
RSV scaffold group (Figure 3.10).
3.4 Discussion
Chronic overnutrition leads to lipid accumulation that has detrimental
consequences such as adipose tissue inflammation and dysregulated insulin signaling
resulting in the progression of metabolic diseases such as obesity and type 2 diabetes129.
Therefore, we are pursuing an approach to combat metabolic disease by enhancing lipid
catabolism in the adipose tissue144. Extensive research shows that resveratrol has the ability
to increase lipid catabolism; however, the molecule’s poor bioavailability proved to be a
great obstacle during clinical trials64,145. As a strategy to overcome this shortcoming, we
incorporated resveratrol into a scaffold for direct delivery to the adipose tissue and
investigated its ability to modulate fat pad size. Mice pre-treated with resveratrol scaffolds
and then fed a high fat diet gained significantly less total body weight and epididymal
adipose tissue mass compared to mice that received scaffolds containing only polymer. The
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effect on total body weight of this localized therapy might not be surprising because the
epididymal fat pad is large, expands quickly, and contributes significantly to total body
weight gain in this model140. Importantly, this scaffold-based strategy required a single
administration compared to previous studies indicating that oral resveratrol delivery
requires daily dosing50,52,61. Furthermore, it is possible that this scaffold-based strategy
could be easily combined with lifestyle interventions, such as calorie restriction and
physical activity, which could further enhance its potential as a promising therapy for
metabolic diseases.
In both lean and high fat diet fed mice, resveratrol scaffolds reduced adipocyte area
compared to PLG scaffolds indicating a reduction in lipid content since adipocyte area and
lipid content are positively correlated146. We propose that resveratrol scaffolds promote
the utilization of lipids within the implant site and that this effect is likely due to the
combination of the host response to biomaterial implant and the release of resveratrol from
the scaffold. The host response exhibited here, characterized by local cellular infiltration
and protein deposition, is similar to wound healing which depends on cellular activity that
is largely fueled by fatty acid metabolism147–149. Furthermore, oral delivery of resveratrol
to animals as well as treatment of cultured cells impacts the activity of several proteins
involved in lipid metabolism, as described in several review articles58,150,151. For example,
treatment of cultured 3T3-L1, porcine, and human adipocytes with resveratrol led to an
increase in lipolysis as a result of elevated ATGL levels52,54,55,60,152. In addition, resveratrol
increased CPT1 mRNA levels in adipose tissue from pigs and rats fed a resveratrol
supplemented diet and cultured adipocytes treated with resveratrol56–58,61,51. Contrary to
our initial hypothesis, scaffold-based resveratrol delivery did not significantly increase
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expression of either ATGL or CPT1 when measured in whole tissue homogenate collected
14 or 28 days after implant. We must consider that measuring these proteins in whole tissue
may have decreased our sensitivity to see significant changes. For example, CPT1 is found
on the mitochondrial membrane; therefore, it may be difficult to measure with high
sensitivity in whole tissue homogenate. It is also possible we did not see differences in
these proteins between scaffold groups at day 28 because the resveratrol payload was
exhausted at that time point. However, we did see increased levels of activated AMPK at
day 14 in the tissue. Literature indicates that resveratrol activates AMPK and resveratrol’s
effect on ATGL and CPT1 are consequences of AMPK activation54,59. Thus, it is possible
that the decreased adipocyte size at day 28 was due to increase in ATGL and CPT1 enzyme
activity at earlier time points.
Remarkably, resveratrol scaffolds protected mice from high fat died induced weight
gain and epididymal fat accumulation 8 weeks after initial implant, while the in vitro
release profile indicates that approximately 70% of the initial resveratrol is released from
the scaffold in the first week. We speculate that as pieces of the scaffold are encapsulated
by the immune system, resveratrol release is slowed, extending its resident time in the
tissue. These potential areas of high resveratrol concentration would more readily impact
cells that are in direct contact. Therefore, we believe that macrophages are a particularly
interesting population for further study as they are recruited to the implant site142 and fuse
together to form multinucleated giant cells that are in direct contact with the scaffold143.
Interestingly, we show that CPT1 is more highly expressed in the newly formed tissue
surrounding the scaffold compared to surrounding adipocytes, and the giant cells were
CPT1 positive. This data is further supported by work that demonstrated that CPT1 is more

67

highly expressed in adipose tissue macrophages compared to adipocytes153. However,
spatial information of CPT1 expression was similar in both resveratrol and PLG scaffolds;
therefore, to further study resveratrol’s potential effect on macrophages, we treated RAW
264.7 macrophages with resveratrol. We found that resveratrol treatment increased CPT1
expression. It has been shown that resveratrol decreases lipid levels in RAW 264.7
macrophages154. Our work suggests that resveratrol decreases lipid levels in RAW 264.7
macrophages through increasing CPT1. In conclusion, we hypothesize that the mechanism
by which resveratrol scaffolds decrease fat pad size relative to blank scaffolds is that upon
scaffold implant, cells are recruited to the implant site, including macrophages, which can
fuse into giant cells, and the resveratrol released increases fatty acid utilization in these
cells leading to decreased adipocyte lipid content reflected in decreased adipocyte size.
While this work demonstrates that resveratrol releasing scaffolds decrease fat pad
size in mice fed a high fat diet compared to scaffolds with no drug, this study does have
limitations. First, we focused on demonstrating a protective effect, which lays a promising
foundation for the technology, but is not translatable to humans as this strategy will likely
be used as an obesity intervention, not a prophylactic. Secondly, we limited the scope of
the study to RSV scaffold’s impact on the epididymal fat pad. Due to differences in
composition and metabolic activity in visceral and subcutaneous fat depots, it remains
unclear if this scaffold-based strategy would achieve similar results in other fat depots.
Furthermore, there is a question of if this strategy would need to target multiple fat depots
simultaneously to observe a significant therapeutic effect in humans. In addition, this study
does not address if the use of scaffolds to enhance lipid metabolism would work in other
metabolically relevant tissues, such as skeletal muscle; however, this is the focus of future
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work. Finally, we must consider that the extensive remodeling that occurred as a result of
the implant may have negative effects on adipose tissue. Future work is focused on
developing injectable technologies that would not induce extensive remodeling but would
rather individually target immune cells to modulate gene programs involved in lipid
catabolism.
In conclusion, implant of resveratrol releasing scaffolds into epididymal fat of lean
mice decreased adipocyte size, a surrogate for lipid content, compared to PLG scaffolds
without a drug payload. Interestingly, the expression of CPT1 and ATGL, key proteins
involved in fatty acid catabolism, whose elevated expression is associated with decreased
adipocyte size, were unchanged in the epididymal fat at 14 or 28 days after scaffold
implant. However, AMPK activation was increased at 14 days, which indicates that ATGL
and CPT1 activity levels could have been elevated, providing a plausible explanation for
the decreased adipocyte size. Histology indicated that scaffold-recruited immune cells
expressed CPT1 at higher levels than other cells in the fat pad and resveratrol increased
CPT1 in cultured macrophages by 30%. Thus, it is possible that our study of whole tissue
homogenates limited our ability to detect increases in CPT1 because it was occurring in a
small population of cells. Taken together, we hypothesize that increases in CPT1 levels
and/or activity in macrophages within the scaffold play a role in resveratrol’s effect on
adipocyte size. We also demonstrate that mice implanted with RSV scaffolds are more
resistant to fat gain during 4 weeks of high fat diet compared to mice that received scaffolds
with no drug. We also demonstrate that mice implanted with resveratrol scaffolds are more
resistant to fat gain during 4 weeks of high fat diet compared to mice that received scaffolds
with no drug. Importantly, this effect was realized with a single administration of scaffolds,
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which is considerably less than the daily dosing regimen usually required for resveratrol’s
weight loss effects on animals fed a high fat diet. We conclude that direct delivery of
resveratrol to the fat tissue overcomes issues with bioavailability and that tissue
engineering scaffolds can be used to achieve this goal. This work motivates further study
into the use of biomaterials for localized delivery of metabolism modulating agents to key
metabolic cells in adipose tissue as a treatment for metabolic disease secondary to overexpanded adipose tissue.
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3.5 Figures

Figure 3.1: Scaffold characterization. (A-D) Scanning electron microscopy and
bright field microscopy images of PLG (A-B) and RSV (C-D) scaffolds. Scale bar
represents 500 µm for B and D. (E) Quantification of pore diameter using ImageJ
analysis of images depicted in B and D. Data was collected from three scaffolds per
group. Statistics were determined using an unpaired t-test. (F-G) Top (F) and side (G)
profile of scaffold implants measuring approximately 5 mm in diameter and 2 mm in
height.
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Figure 3.2: Resveratrol release profile. One-week in vitro release profile of
resveratrol loaded PLG scaffolds. Data are from 3-8 scaffolds per time point. Error bars
denote SEM.
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Figure 3.3: Epididymal adipose tissue remodeling after resveratrol scaffold
implant. (A-F) Histological sections of epididymal fat pads 28 days after implant of
PLG (A-C) or RSV (D-F) scaffolds at 4x (A,D) or 40x (B,C,E,F) magnification. Scale
bar represents 500 µm for A and D and 50 µm for B, C, E, and F. (G) Quantification of
adipocyte area. Data was collected from 3 40x images per section, with 3 sections per
mouse and 3 mice per group. Statistics were calculated by an unpaired t-test. * p<0.05
compared to PLG.
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Figure 3.4: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation
protein expression 28 days after implant in lean mice. (A) Representative western
blots of ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK
(Thr172), and total AMPK protein expression in adipose homogenates 28 days after
implant. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK
expression. Data is from 3 mice per group. Statistics were calculated using an unpaired
t-test.
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Figure 3.5: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation
protein expression 14 days after implant in lean mice. (A) Representative western
blots of ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK
(Thr172), and total AMPK protein expression in adipose homogenates 14 days after
implant. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK
expression. Data is from 4 mice per group. Statistics were calculated using an unpaired
t-test. * indicates p<0.05 compared to PLG.
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Figure 3.6: Spatial analysis of CPT1 in the epididymal fat pad after scaffold
implant. (A-D) CPT1 stained histological sections of epididymal fat pads 28 days after
implant of PLG (A,C) or RSV (B,D) scaffolds at 4x (A,B) or 40x (C,D) magnification.
Scale bar represents 500 µm for A-B and 50 µm for C-D. Data is representative of 3
sections per mouse with 3 mice per group.
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Figure 3.7: Effect of resveratrol on CPT1 expression in RAW 264.7 macrophages.
Representative western blot of CPT1 protein expression in RAW 264.7 macrophages
treated with 0, 10, or 25 µM RSV for 24 hours. (B) Quantification of CPT1 expression.
Data is from three 6 well plates with 2 wells per group on each plate. Statistics were
calculated using a one-way ANOVA with a Tukey’s multiple comparison test.
*indicated p<0.05 compared to untreated (0 µM).
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Figure 3.8: Impact of scaffolds on weight gain and epididymal fat pad mass in mice
challenged with a high fat diet. (A) Timeline of experiment. (B) Percent increase in
fasting body weight relative to day 0 when the high fat diet began. (C) Epididymal fat
pad weight 28 days after high fat diet challenge. N=5 mice per group. Statistics were
conducted using an unpaired t-test. *indicates p<0.05 compared to PLG.
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Figure 3.9: Effects of resveratrol scaffolds on epididymal fat adipocyte size after
high fat diet challenge. (A-B) Histological sections of epididymal fat pads that received
(A) PLG or (B) RSV scaffolds 28 days after high fat diet challenge taken at 40x
magnification. Scale bar represents 50 µm. (C) Quantification of adipocyte area. Data
collected from3 images per section, with 3 sections per mouse and 3 mice per group.
Statistics were calculated using an unpaired t-test. *indicates p<0.05 compared to PLG.

79

Figure 3.10: Effects of resveratrol scaffolds on key lipolysis and fatty acid oxidation
protein expression after high fat diet challenge. (A) Representative western blots of
ATGL, CPT1, phosphorylated ACC (Ser79), total ACC, phosphorylated AMPK
(Thr172), and total AMPK protein expression in adipose homogenates after high fat diet
challenge. (B-E) Quantification of (B) ATGL, (C) CPT1, (D) ACC, and (E) AMPK
expression. Data is from 5 mice per group. Statistics were calculated using an unpaired
t-test. * indicates p<0.05 compared to PLG.
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CHAPTER 4
SINGLE BOLUS DOXORUBICIN ADMINISTRATION INDUCES
FIBROSIS IN SUBCUTANEOUS ADIPOSE TISSUE: A THERAPEUTIC
OPPORTUNITY3
4.1 Introduction
Cachexia is a condition associated with involuntary skeletal muscle and adipose
tissue atrophy resulting in weight loss that affects 50-80% of cancer patients and is
responsible for approximately 20% of cancer-related deaths67,68. This debilitating symptom
of cancer progression significantly reduces patient quality of life and correlates with
worsened prognosis68. Patients that receive cytotoxic chemotherapy treatments often
present with changes in body mass and composition155. Additionally, ovarian cancer
patients have a worse survival rate when they lose skeletal muscle and adipose tissue mass
while undergoing chemotherapy treatment156. Therefore, this condition may be, in part,
related to the use of chemotherapies, such as doxorubicin. Doxorubicin is an extensively
used chemotherapeutic agent for the treatment of a wide variety of cancers, including
leukemia, stomach, breast, and ovarian157. Treatment with this chemotherapy is associated
with cardiotoxicity, nephrotoxicity, and hepatotoxicity, in addition to other severe and
unpleasant side effects72. Doxorubicin’s negative effects on adipose tissue function may
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play a role in cachexia development; however, only few pre-clinical studies have
characterized the impact of doxorubicin treatment on adipose tissue function71–73.
Adipose tissue is most notably known for its role as a lipid storage site, but this
tissue also controls metabolism, immunity, reproduction, and many other processes
required for homeostasis through the factors it

8,12,158,159

. Therefore, dysfunction of this

tissue can lead to a host of systemic complications, such as chronic systemic inflammation
and insulin resistance, which contribute to a type 2 diabetic like state. Biopsies from
cachexic cancer patients have presented with subcutaneous adipose tissue architectural
remodeling, such as decreased adipocyte area, increased inflammatory cell infiltration, and
fibrosis74. Fibrosis is defined as the excessive deposition of extracellular matrix proteins,
including collagen 1, which is a key provider of the major structural framework of adipose
tissue160. During obesity related fibrosis, macrophages recruited to the site of injury are
known to be the key regulator of fibrosis75. These cells produce soluble factors, such as
TGF-B1, that activate fibroblasts already within the tissue as well as factors that recruit
new fibroblasts75. Activated fibroblasts possess an increase in α-smooth muscle actin and
lay down extracellular matrix proteins, such as collagen 1161. Fibrosis has significantly
negative consequences to adipose tissue function and as a result to systemic processes
controlled by the adipose tissue75. Fibrosis limits cell to cell communication required for
proper function and induces a rigidness that reduces flexibility, resulting in decreased lipid
storage capacity and consequently lipid deposition in distant tissues75. This rigidness is also
likely to be uncomfortable for the patient leading to a decreased quality of life.
Furthermore, fibrosis alters the adipose tissue secretome by reducing the secretion of health
promoting factors, such as adiponectin, which promotes insulin resistance75.
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There is limited literature investigating doxorubicin’s impact on adipocyte lipid
metabolism71–73,162,163; however, even fewer studies have aimed to understand
doxorubicin’s role in promoting adipose tissue remodeling similar to that observed in
cachexic cancer patients71. Furthermore, there are several critical, unanswered questions
that should be addressed regarding the role of doxorubicin administered dose, dosing
schedule, and the gender of the studied population. To date, most in vivo work studying
doxorubicin’s effect on adipose tissue has been tested in male rodents by injecting small
dosages multiple times over several weeks. However, this does not accurately model
clinical dosages of most cancer patients. A common patient dose of doxorubicin is 60
mg/m2 administered once every 21 days, therefore, when scaled to rodents this is equivalent
to a 20 mg/kg dose164. However, it is unknown how adipose tissue responds to this larger
bolus after 72 hours, since only few have assessed larger dose at early time points165.
Furthermore, there is a significant need to study the effect of this chemotherapy on adipose
tissue in female rodents, as to our knowledge this response has never been reported. Since
doxorubicin is used to treat several female cancer, such as breast and ovarian cancer157,
and adipose tissue wasting is associated with worsened prognosis in ovarian cancer
patients156, it is imperative that doxorubicin’s role to promote adipose tissue dysfunction
in females is investigated.
Therefore, to begin to address these gaps in literature, the overall aim of this
manuscript was to characterize the effects of a clinically relevant bolus of doxorubicin on
adipose tissue fibrosis in female rats. Visceral and subcutaneous adipose tissue depots were
studied to determine if anatomical location was a factor involved in the extensiveness of
doxorubicin induced fibrosis, a response not yet investigated. This work is expected to
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provide greater understanding of doxorubicin’s potential role in promoting cancerassociated cachexia and provide insight for the development of future strategies to sustain
adipose tissue health during chemotherapy treatment.
4.2 Materials and Methods
4.2.1 Animal Study Design
The Animal Care and Use Committee of the University of South Carolina approved
these experiments. Adult four-six-month old female Sprague-Dawley rats were maintained
on a 12:12 h reverse light-dark cycle and provided rat chow and water ad libitum. Figure
4.1A illustrates the timeline of the study. A cohort of Sprague-Dawley female rats were
weighed on day 0 and then randomly assigned to either receive a bolus of doxorubicin
hydrochloride (20 mg/kg body weight) via intraperitoneal injection or equal volumes of
saline. Animals were monitored daily. Due to a decline in animal health, the number of
animals actually studied in each group was reduced. Furthermore, the end point of the study
was changed from 14 to 9 days due to animal health. At the end of the study, 5 animals that
had received doxorubicin and 6 animals that received equal volumes of saline were studied.
On day 9, animals were weighed and then acutely anesthetized with sodium
pentobarbital (60 mg/kg intraperitoneally). After reaching a surgical plane of anesthesia,
the heart was removed for mechanistic studies conducted by the Smuder group. Following
euthanasia, approximately 200-400 mg of the ovarian or inguinal fat pads were submerged
in 4% paraformaldehyde for histological analysis. The rest of the ovarian and inguinal fat
pads were flash frozen in liquid nitrogen and stored at -80°C for protein or triglyceride
analysis.
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4.2.2 Histological Analysis
Ovarian and inguinal fat was fixed in 4% paraformaldehyde, embedded in paraffin,
and serially cross-sectioned into 5 µm sections. Sections were stained with hematoxylin
and eosin (H&E) for morphological analysis. Using a Nikon Eclipse ci microscope, three
random images were taken at 20x magnification of four sections per fat pad per animal.
Image J software was used to quantify adipocyte area from 4 sections per tissue from 4
saline injected animals and 5 Dox treated animals. All adipocytes within the field of view
were quantified. Adipocyte number in each field of view is also reported.
4.2.3 Triglyceride Quantification
Triglycerides in ovarian and inguinal fat were quantified using the Triglyceride
Colorimetric Assay kit purchased from Cayman Chemical. The measurements were made
according to the manufacturer’s instructions. Briefly, frozen fat pads (150 mg) were
homogenized in 750 µL of diluted NP40 Substitute Assay Reagent containing Halt
Protease Inhibitor Cocktail (Thermo Fisher Scientific) using a benchtop homogenizer.
Samples were centrifuged at 10,000 x g for 10 minutes at 4 °C and the supernatant was
collected and stored at -80°C until analyzed. Samples were added to a 96-well plate and a
coupled enzymatic reaction was initiated to hydrolyze triglycerides in the samples to
produce glycerol and fatty acids. After a 15-minute incubation, the plate was analyzed at
540 nm using a spectrophotometer. A standard curve was used to extrapolate triglyceride
concentration in mg/dl in the unknown samples. Triglyceride content was reported as mg
triglyceride per g homogenized tissue.
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4.2.4 Protein Quantification
Frozen fat pads (approximately 500 grams) were homogenized in a defined volume
of RIPA buffer (Fisher Scientific) containing Halt Protease Inhibitor Cocktail (Thermo
Fisher Scientific), PhosStop (Sigma), and PMSF (Thermo Fisher Scientific) using a
benchtop homogenizer. Centrifugation was used to removal all insoluble material and the
supernatant was collected, aliquoted, and stored at -80 °C. Total protein in the homogenate
was quantified using the Pierce BCA protein assay kit (Thermo Fisher Scientific). Total
protein is reported as mg protein per gram of homogenized tissue.
4.2.5 Western Blotting
Ten-thirty µg protein was separated by 8% polyacrylamide gel electrophoresis and
then transferred to 0.2 µm nitrocellulose membranes. Membranes were then blocked with
5% nonfat dry milk in Tris-buffered saline containing Tween-20 (TBST) for 1 hour at room
temperature. Primary antibody for anti-collagen 1 (Abcam) and anti-α smooth muscle actin
(Cell Signaling Technologies) was added to each blot at 1:1000 dilution in 5% BSA in
TBST and allowed to incubate overnight at 4°C before incubation with a polyclonal
secondary antibody conjugated to horseradish peroxidase (Abcam) in 5% milk for 1 hour
at room temperature. The blots were developed with SuperSignal enhanced
chemiluminescent substrate solution (Thermo Fisher Scientific). To verify loading, blots
were incubated with stripping buffer for 25 minutes and washed with TBST. The blot
underwent the same protocol as previously stated for β-actin (Sigma) using a monoclonal
secondary antibody conjugated to horseradish peroxidase (Biorad). ImageLabs software
was used to analyze the relative intensity of each protein. Results were reported as intensity
of the primary antibody relative to the intensity of β-actin.
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4.2.6 Statistical Analysis
Statistically significant differences between saline and Dox treated groups were
evaluated using an unpaired student’s t-test. Statistical significance was set to a p value
less than 0.05. The number of samples analyzed is detailed in each figure legend. All
analyses were completed using GraphPad Prism. In all figures, data is presented as
individual data points from each rat analyzed with mean and standard deviation.
4.3 Results
4.3.1 Effect of Doxorubicin on Animal Body Weight and Fat Pad Mass
As anticipated, a 20 mg/kg intraperitoneal Dox bolus significantly reduced the body
weight of treated animals compared to the saline group 9 days after administration (Figure
4.1B). Additionally, Dox reduced animal body weight by approximately 20% when
comparing body weight measured prior to injection and before euthanasia on day 9 (Figure
4.1C). However, to our surprise, the weight of the ovarian (Figure 4.1D) and the inguinal
(Figure 4.1E) fat pads normalized to body weight did not significantly change 9 days after
Dox treatment compared to saline injected controls. Additionally, there is significant
variability between the Dox treated animals in body weight and fat pad weights that is not
observed in the saline control group. For example, the body weight of Dox treated animals
changed anywhere from losing 33% of their body weight to gaining 2% of their body
weight (Figure 4.1B).
4.3.2 Adipose Tissue Remodeling in Doxorubicin Treated Animals
Since cancer induced cachexia patients present with changes in adipose tissue
remodeling such as extracellular matrix deposition, cellular infiltration, and reduced
adipocyte area74, both the ovarian and inguinal fat pads were histologically assessed 9 days
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after Dox treatment. Figure 4.2 shows representative tissue sections of saline and Dox
treated ovarian (Figure 4.2A-B) and inguinal (Figure 4.2 C-D) stained with hematoxylin
and eosin. We did not detect major differences between ovarian fat collected from saline
rats compared to healthy ovarian fat (data not shown). Furthermore, we observed a slight
increase in cellular infiltration (purple arrow), extracellular matrix deposition (yellow
arrow), and vessel formation (red arrow) surrounding adipocytes in Dox treated ovarian fat
(Figure 4.2B). Compared to the ovarian fat, the inguinal fat inherently has less adipocytes,
larger intercellular space, increased blood vessels (red arrow), and an inherent abundance
of collagen fibers (yellow arrows) as seen in inguinal fat collected from saline treated rats
(Figure 2.4 C). Doxorubicin treatment enhanced the abundance of extracellular matrix
proteins within the inguinal fat compared to saline control (Figure 4.2D compared to C).
Furthermore, Dox treatment established a more severe fibrotic response in the inguinal fat
compared to the ovarian fat, as supported by a significant increase in extracellular matrix
deposition in Figure 4.2D compared to Figure 4.2B.
As a quantitative, surrogate method to measure the extent of fibrosis in both tissues
as a function of Dox treatment, total protein content in both fat pads was measured (Figure
4.3). Total protein was not significantly altered with Dox treatment compared to saline in
either ovarian or inguinal fat, but there was an upward trend observed in both tissues. As
observed in the weight measurements, there was large variability in this measurement
between the Dox treated animals. Similarly, the extent to which Dox induced fibrosis in
the inguinal fat as observed histologically was highly variable. The image shown in Figure
4.2D is deemed as the average extent of fibrosis and is associated with the individual data
point closest to the average total protein content in Figure 4.3B. Large variability was not
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observed histologically between Dox treated ovarian fat pads, likely because Dox induced
inflammation was not as severe in this fat pad compared to the inguinal.
Upon this observation, we investigated a possible mechanism for the severe fibrosis
that occurred in inguinal fat pads by measuring collagen 1 and α-smooth muscle actin (αSMA) within inguinal adipose tissue homogenate using western blot (Figure 4.4A).
Interestingly, both collagen 1 (Figure 4.4B, p=0.042) and α-SMA (Figure 4.4C, p=0.054)
relative to β-actin were significantly increased in inguinal fat pads collected from Dox
treated animals as determined by an unpaired student’s t-test. This data suggests a possible
role of activated fibroblasts in this fibrotic response induced by Dox treatment that warrants
further dissection.
4.3.3 Adipocyte Morphological Changes in Doxorubicin Treated Animals
Adipose tissue function is highly dictated by adipocyte function; therefore, we then
investigated how Dox treatment altered adipocyte area and number in ovarian and inguinal
fat pads by further investigating H&E stained sections shown in Figure 4.2. Adipocytes in
ovarian fat pads collected from Dox treated animals looked to be smaller (Figure 4.5A
compared to B); however, upon quantification using ImageJ, adipocytes were not
significantly smaller in area compared to the saline treated group (Figure 4.5E), but there
was a decreasing trend observed. However, there were significantly more adipocytes within
each frame indicating a potential state of hyperplasia (Figure 4.5F). Similarly, adipocytes
in inguinal fat pads collected from Dox treated animals also appeared to be smaller in
stained sections (Figure 4.5C compared to D); however, upon quantification there was not
a significant difference in adipocyte area or number between groups. Once again, we
observed large variability in the quantification between Dox treated animals, especially in
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the inguinal fat analysis. The histological image in Figure 4.5D is associated with the
individual data point in Figure4.5G and H closest to the mean. To test the hypothesis that
Dox treatment reduced triglyceride content as suggested by a reduction in adipocyte area,
we measured total triglyceride content in each tissue (Figure 4.6). In ovarian and inguinal
fat, triglyceride content was not significantly reduced with Dox treatment, and in fact
trended upward compared to saline injected animals. To our surprise, the animals that
exhibited smaller adipocyte area measured to have more triglycerides within the tissue.
4.4 Discussion
Cachexia is a significant symptom of cancer progression that leads to
approximately 20% of cancer-related deaths and a major reduction in the patient’s quality
of life. Because patients that receive cytotoxic chemotherapy treatments often present with
changes in body mass and composition155, it is likely that chemotherapy plays a role in
progressing this condition. Doxorubicin is a widely used chemotherapeutic with severe
cytotoxic effects on the heart, liver, and kidney157; however, the role of doxorubicin
administration on adipose tissue wasting remains unclear. In this report, we demonstrated
that a 20 mg/kg bolus of Dox significantly reduced body weight, but not adipose tissue
weight, and differentially promoted fibrosis of adipose tissue depots 9 days after injection
in female rats. To our knowledge, these results are the first to suggest that Dox induced
adipose tissue fibrosis also occurs in female rodents and varies based on adipose tissue
anatomical location.
Our results indicate a significant importance of Dox administration, such as dose
and study duration, on adipose tissue function. A single 20 mg/kg doxorubicin bolus was
chosen for this study because it represents a relevant clinical human dose scaled to rodents.
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This dose has been used to evaluate Dox effects on skeletal muscle166 and heart165;
however, the effect of Dox on adipose tissue at this dose has yet to be investigated. Our
results indicate 9 days after injection, Dox significantly reduced animal body weight, which
is a similar response demonstrated by studies that administered this dose, but ended the
study 24-72 hours after injection165,167. Furthermore, our results did not indicate a
significant reduction in ovarian (perigonadal) or inguinal (subcutaneous) fat or adipocyte
area in either tissue. We hypothesize that body weight changed due to Dox induced changes
in other organs such as skeletal muscle166. Contrary to our results, when 2.5 mg/kg Dox
was administered twice per week for two weeks, rodents maintained their body weight,
significantly lost perigonadal and subcutaneous adipose tissue mass, and observed a
significant reduction in adipocyte area in subcutaneous tissue71. However, when
administering Dox as either a single, large bolus or multiple small injections, fibrosis
occurred in subcutaneous tissue and was associated with an increase in collagen71. This
leads to the conclusion that dose and administration schedule may have an impact on how
Dox impacts adipose tissue.
Pre-clinical studies have determined that Dox induces fibrosis and inflammation in
several organs, such as the liver168 and heart169, but there is limited knowledge on Dox’s
fibrotic effect on adipose tissue. Similar to a previous report71, we demonstrated that a Dox
bolus induced fibrosis in subcutaneous adipose tissue. Dox induced adipose tissue fibrosis
was associated with an elevation in collagen 1 and α-smooth muscle actin expression, a
marker of activated fibroblasts161. Therefore, we propose the mechanism of this response
may be two-fold: 1) Dox stimulates the infiltration of macrophages that in turn activate
fibroblasts to synthesize extracellular matrix proteins via secreted soluble factors and/or 2)
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Dox directly activates fibroblasts to synthesize extracellular matrix proteins. This
hypothesis is supported by literature suggesting that Dox treatment increases infiltration of
macrophages at injured site, as observed in Dox induced nephropathy170, and also activates
cardiac fibroblasts which led to an elevation in α-smooth muscle actin expression and
collagen 1 expression171.

Additionally, this fibrotic response was similar to that in

subcutaneous adipose tissue biopsies from cancer cachexic patients characterized by an
elevation in collagen 1, α-smooth muscle actin74,172. Furthermore, cachexic patient biopsies
also indicated altered TGF-β signaling, suggesting a possible role for TGF-β in Dox
induced adipose tissue fibrosis, which should be a focus of future studies.
Furthermore, in this report, we established for the first time that Dox more severely
induces a fibrotic response in inguinal fat, a subcutaneous fat pad, compared to ovarian fat,
a visceral fat pad, in female rats. This is particularly interesting because in this study Dox
was administered intraperitoneally, where the ovarian fat was bathed in the drug upon
injection. We hypothesize that inherent differences in composition and function between
visceral and subcutaneous fat pads may play a role in this altered effect. One such
difference is that subcutaneous fat has higher basal levels of PPARγ, a nuclear receptor
involved in adipocyte differentiation and is also more responsive to PPARγ ligands, such
as thiazolidinediones34,173. If this tissue is more responsive to PPARγ ligands, then it’s
possible that it could be more sensitive to agents that inhibit PPARγ, such as Dox174.
Additionally, activation of PPARγ can block TGF-β signaling and thus fibrosis175.
Therefore, the subcutaneous fat may be more fibrotic due its heightened sensitivity to
PPARγ inhibition after Dox leading to the enhanced TGF-β induced fibrosis.
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The data set reported here exhibited large variability associated with the Dox
treated animals. It is hypothesized that this large variability is associated with the use of
female rats in the study. This is the first time that adipose tissue dysfunction has been
reported in female rats; however, in a study using male rodents, there doesn’t appear to be
large variances in data collected from adipose tissue, even when using a small sample
size71. Sexual dimorphism has been established in Dox induced toxicities as female rodents
have shown to be protected against Dox induced cardiotoxicity compared to males176.
Therefore, some animals appeared to be more resistant than others to Dox treatment
potentially due to differences associated with the fact that they are female. Furthermore,
fluctuations in female reproductive hormones in response to estrous cycles could
complicate the system and potentially be a source of data variability between Dox treated
animals. Fluctuations in sex hormones plays a significant role in adipose tissue metabolic
function; for example, a decrease in estrogen is associated with an increase in fat pad
weight177. Further investigation is warranted on sexual dimorphism and the role of female
sex hormones on Dox induced adipose tissue dysfunction. This is especially important to
understand for ovarian cancer patients, a population in which chemotherapy induced
adipose tissue wasting is associated with lower survival156.
Since adipose tissue wasting is a main component of cancer associated cachexia,
and is in part due to toxic chemotherapies, there is a significant need for novel therapies to
sustain adipose tissue health and metabolic function during chemotherapy treatment. We
propose in future studies to utilize particle delivery systems that are easily injected into the
subcutaneous fat pad to target macrophages as a strategy to prevent doxorubicin induce
adipose tissue fibrosis. The results presented here indicate that a chronic Dox bolus maybe
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an appropriate therapeutic testing model for the development of adipose tissue fibrosis in
female cancer patients; however, to maintain 100% animal survival, further investigation
into adipose tissue dysfunction of clinically relevant dosage and schedules is needed.

4.5 Figures

Figure 4.1: Study timeline, body weight change, and fat pad mass 9 days after Dox
administration. (A) Study timeline. (B-C) Body weight (B) and body weight percent
change (C). (D-E) Ovarian (D) and inguinal (E) adipose tissue mass. Data is from n=5
Dox treated animals and n=6 saline controls. Data is presented as individual data points
with mean ± standard deviation.
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Figure 4.2: OWAT and IWAT histological analysis. (A-D) Histological sections of
ovarian (A,B) and inguinal (C,D) fat pads collected 9 days after saline (A,C) and Dox
(B,D) injection stained with hematoxylin and eosins. Scale bar represents 500 µm.

Figure 4.3: Effect of Dox administration on total protein content 9 days after
injection. Protein content measured in (A) ovarian and (B) inguinal fat pads. Data is
collected from n=6 saline injected rats and n=5 Dox treated rats. Statistics determined
using an unpaired student’s t-test.
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Figure 4.4: Effect of Dox administration on profibrotic proteins. (A) Representative
western blots of collagen 1 and α-smooth muscle actin expression in inguinal adipose
homogenate 9 days after treatment. (B-C) Quantification of (B) collagen 1 and (C) αsmooth muscle. Data is collected from n=6 saline injected rats and n=5 Dox treated rats.
Statistics determined using unpaired student’s t-test. * indicates p<0.05 compared to
saline.

Figure 4.5: OWAT and IWAT adipocyte area and number 9 days after Dox
administration. (A-D) Histological sections of ovarian (A,B) and inguinal (C,D) fat
pads collected 9 days after saline (A,C) and Dox (B,D) injection stained with
hematoxylin and eosin. Scale bar represents 100 µm. (E-H) Quantification of adipocyte
area (E,G) and number (F,H) from ovarian (E,F) and inguinal (G,H) fat pads. Data was
collected from 3 random 20x images per section, with 4 sections per fat pad, and 4-5
rats per group. Statistics determined using an unpaired student’s t-test. * indicates
p<0.05.
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Figure 4.6: Effect of Dox administration on triglyceride content 9 days after
administration. Triglyceride content was measured in (A) ovarian and (B) inguinal fat
pads. Data is collected from n=6 saline injected rats and n=5 Dox treated rats. Statistics
determined using an unpaired student’s t-test.
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CHAPTER 5
CONCLUDING REMARKS AND FUTURE DIRECTIONS
5.1 Concluding Remarks
Once known as an inert site for lipid storage, the adipose tissue has recently become
well accepted as an endocrine organ that plays a key role in whole body homeostasis. The
ability to directly modulate its inherent endocrine and metabolic functions has promising
implications in treating diseases associated with adipose tissue dysfunction. One such
example is obesity, in which a significant portion of the United States adult population has
been diagnosed, a trend that continues to rise. Since obesity is a critical risk factor for
numerous severe and chronic diseases, this epidemic has become an ever increasing
economic and health burden. With the current interventions possessing substantial
challenges, novel therapeutic platforms engineered to specifically target the adipose
tissue’s metabolic and endocrine function are warranted. One central objective of this work
was to test the effectiveness of scaffold-based delivery of resveratrol, a promising antiobesity drug that suffers from poor bioavailability, to reduce inflammation and lipid
accumulation upon implant into the adipose tissue and thus establish its potential as an antiobesity therapeutic platform.
The first aim accomplished this objective by further understanding how the immune
compartment within the adipose tissue was altered after poly(lactide-co-glycolide) scaffold
implant and how the incorporation of resveratrol modulated this response. This was
particularly important to understand as inflammation drives metabolic disease within the
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adipose tissue. Resveratrol was successfully incorporated into the polymer matrix with
high resveratrol loading and exhibited a drug release with a burst followed by a plateau
phase. In addition, resveratrol loaded materials maintained their loading and activity for at
least a year. The in vivo results of this aim, outlined in Chapter 2, demonstrated that the
incorporation of resveratrol augments an anti-inflammatory environment established by
PLG scaffolds, characterized by low levels of pro-inflammatory cytokines and increased
expression of anti-inflammatory cytokines upon implant in lean mice. More therapeutically
relevant were the results that treatment with resveratrol scaffolds decreased inflammatory
cytokines in mice challenged with a high fat diet and adipocytes treated with a
inflammatory stimulus. This work demonstrates to the tissue engineering community that
PLG scaffolds are a promising platform for the treatment of adipose tissue inflammation,
which drives metabolic disease, due to their ability to promote an anti-inflammatory
environment and their feasibility to be engineered as drug delivery vehicles.
The goal of the second aim, described in Chapter 3, was to investigate resveratrol
scaffold-based delivery to enhance lipid catabolism within the adipose tissue. Implant of
resveratrol scaffolds in lean mice decreased adipocyte size relative to scaffolds with no
drug pay load, which is a surrogate measurement of lipid load within the cells. Furthermore,
the results support the hypothesis that resveratrol scaffolds decrease adipocyte size because
resveratrol increases lipid utilization in scaffold-infiltrating immune cells, potentially by
elevating expression or activity of the rate limiting enzyme in fatty acid oxidation.
Importantly, mice pre-treated with resveratrol scaffolds prior to high fat diet feeding
exhibited decreased weight gain, adipose tissue expansion, and adipocyte hypertrophy
compared to scaffolds without a drug payload. This was the first study of its kind to indicate
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that a single administration of resveratrol via PLG scaffold delivery was as successful in
preventing weight gain compared to the daily regiment generally needed for oral delivery.
These results indicate that localized delivery of metabolism modulating agents directly to
the tissue of interest may overcome poor bioavailability. Taken together with the results
described in Chapter 2, this work demonstrates to the tissue engineering field that PLG
scaffolds are not only a suitable platform for adipose tissue regeneration and in vitro model
development, but also a promising platform for local drug delivery to the adipose tissue.
Furthermore, this strategy has the potential to be a promising therapeutic anti-obesity
strategy through its ability to direct adipose tissue inflammatory and metabolic programs.
In addition to obesity, cachexia is a debilitating disease that is associated with
adipose tissue wasting and inflammation and decreases the quality of life for a significant
number of cancer patients. In the work described in chapter 4, we aimed to establish how
a doxorubicin bolus impacted adipose tissue remodeling in female mice, a response that
had yet to be reported, but is significant since a large portion of doxorubicin treated patients
are women. Doxorubicin treatment significantly reduced body weight, but treatment did
not decrease adipose tissue mass or adipocyte area. Furthermore, significant fibrosis
occurred in subcutaneous adipose tissue to a greater extent than visceral that was associated
with an increase in expression of a fibroblast activation marker and collagen, a response
similarly found in human cachexia patients. These results provide further understanding
of how chemotherapy can potentially promote cachexia, a disease that leads to 20% of
cancer deaths. Furthermore, this work may provide insight for the development of future
platforms to sustain adipose tissue health during chemotherapy treatment.
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5.2 Future Directions
While Chapters 2 and 3 undoubtedly demonstrate that resveratrol loaded scaffold
delivery is a promising strategy for directing adipose tissue function, there are several
challenges that this strategy must overcome in order to increase its future translatability.
Overcoming these challenges should be a major focus of future work. The first challenge
is that as its been studied so far, the implantation process requires an invasive surgical
procedure in which the abdominal cavity is opened. This could be alleviated in two ways:
1) target a subcutaneous fat pad or 2) develop an injectable system that would not require
an implant surgery. Targeting a subcutaneous fat pad would allow for the scaffold to be
implanted via a small incision and a trocar. However, this strategy has not been studied in
subcutaneous fat pads; therefore, we do not know if this strategy will have the same
beneficial effects in subcutaneous fat due to differences in composition and metabolic
activity in visceral and subcutaneous fat depots. Additionally, developing an injectable
system would bypass the need for surgical procedures and would allow for targeting of any
fat depot.
Secondly, this strategy is associated with extensive remodeling where the immune
system encapsulates the material due to its inability to remove the material. As elaborated
on in Chapter 4, this fibrotic response can have negative effects on adipose tissue function.
Therefore, future work should focus on developing an injectable technology that would
also not induce extensive remodeling. Literature suggests that a promising strategy would
be to develop a particle system that would rather individually target immune cells to
modulate gene programs involved in inflammation and metabolism.
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Finally, the release kinetics of resveratrol from the scaffold should be improved.
The current fabrication technique results in a scaffold that is loaded with a large amount of
resveratrol that releases in a burst phase followed by a plateau phase. This was strategic
when desiring to modulate the acute inflammatory phase which occurs in the first few days
following implant; however, it is likely that extended release over longer periods of time
will enhance its effectiveness as a therapeutic for metabolic disease. Furthermore, even
though we saw an increase in anti-inflammatory cytokines in Chapter 2, an initial increase
in neutrophils occurred that was likely counterproductive and potentially due to the burst
release of resveratrol from the scaffold. Fabrication parameters that could be tailored in
order to extend this release are polymer molecular weight and the amount of resveratrol
loaded within the scaffold. Increasing the polymer molecular weight and decreasing the
amount of resveratrol loaded is likely to reduce the burst release and extend the release
from the scaffold over time.
In Chapter 4, the effect of Doxorubicin to induce adipose tissue fibrosis in female
rats was demonstrated. In the model used in this study, the dose and study timeframe were
associated with decreased animal survival. Therefore, further understanding of the adipose
tissue fibrosis that results after i.p. injection of a clinically relevant dose given for a shorter
time is likely necessary to maintain animal survival. Furthermore, there is a therapeutic
opportunity to use biomaterials to sustain adipose tissue health during chemotherapy
treatment. Therefore, a particle drug delivery system could be designed to inhibit fibrosis
by locally delivering a potent anti-inflammatory molecule or targeting macrophage
inflammatory function. This doxorubicin induced fibrosis model could be utilized to test
the efficacy of these therapeutic systems in future studies. Collectively, the future
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improvements and studies discussed could lead to the development of potentially lifesaving therapeutic strategies for adipose tissue dysfunction associated with obesity and
cachexia.
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APPENDIX A
BEST PRACTICES FOR WESTERN BLOTTING
Western blotting is a technique that is extensively used in biological research to
determine relative expression of specific proteins in the sample. There are several online
resources that one can take advantage of to learn this technique (doi:10.4103/19472714.100998, 10.1111/sms.12702, and Biorad’s Introduction to Western Blotting
webpage). However, over the course of my Ph.D., I have analyzed lysate from cell culture
experiments and collected adipose tissue from animal experiments and the techniques that
I have learned while running these experiments are detailed below.
A.1 Sample collection and storage
When analyzing protein from either cells or tissues, the first thing that must be done
is to isolate the protein fraction from your sample. There is a specific protocol for cells
collected from cell culture and tissues collected from animal studies. The homogenization
buffer consisting of RIPA buffer, 100x PhosStop, 100x PMSF, and 100x protease inhibitor
cocktail is the same for both samples. To lyse RAW 264.7 cells, 100 µL of the
homogenization buffer should be added to each sample for experiments where more than
200,000 cells were seeded. I would suggest decreasing the cell volume to 75 µL for
experiments where fewer than 200,000 Raw 264.7 cells were seeded. When using 3T3-L1
cells, experiments with 80,000 cells per well or greater can be homogenized in 100 µL.
Cells are then lysed using a needle and syringe. Do not create bubbles during lysing. The
homogenized cells are then centrifuged and the supernatant (protein fraction) is collected
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from the top. Be careful not to disturb the pellet at the bottom. Supernatant is aliquoted into
appropriately labeled tubes and stored in the -80°C freezer
For tissues, the tissues are first weighed (usually this is done upon collection from
the animal prior to freezing) and placed into a 2 mL round bottom tube. It is important that
they are placed in a round bottom tube because the homogenizer tip can fully reach the
bottom of the tube during homogenization, which it cannot when using a 1.7 mL conical
tube. The samples are to be kept on ice at all times. Homogenization buffer is added to the
tissue at a volume (µL) that is 4 x tissue mass (mg). If the tissue is larger than 250 mg
(addition of 1mL buffer), I suggest splitting the tissue into multiple 2 mL round bottom
tubes. This will ensure that the liquid does not overflow during homogenization. A pair of
surgical scissors is then used to finely mince each tissue and the samples are then placed
on the rocker in the fridge for 45 minutes. Be sure that when they are placed on the rocker,
they are placed longways and ensure that the solution is moving up and down within the
tube. The large homogenizer tip used for particle fabrication should be exchanged for the
smaller tip and cleaned with ethanol and water prior to homogenization. Be sure to have
reserved the homogenizer on the google calendar or talked with lab mates prior to planning
the homogenization. Each sample will be homogenized for 3x1min at 10,000 rpm. I suggest
homogenizing each sample in one experimental group once and then repeating all of them
2 more times. This will ensure each sample stays as cold as possible. The homogenizer
must be cleaned between each sample using water and ethanol. The microcentrifuge should
be “fast temped” to 4°C prior to centrifugation of samples at 18,000 xg for 45 minutes.
Supernatant is collected from samples, aliquoted into appropriately labeled tubes and
stored in -80°C freezer. Be sure not to disturb the pellet at the bottom. For fatty tissues,
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such as adipose tissue, there will also be an insoluble fatty cake on the top. I found that the
easiest way to deal with this layer is to push it to the side or even out using a 1000 µL
pipette tip.
A.2 Total protein analysis
In order to appropriately compare the result from each sample, the amount of total
protein analyzed must be the same for each sample. Therefore, a BCA assay is used to
determine the amount of total protein in each sample. A 2 mg/mL bovine serum albumin
aliquot is diluted in homogenization buffer to create a standard curve to which the unknown
samples will be compared. Usually, each sample is added to the 96 well plate using a 1:5
or 1:2 ratio of sample to homogenization buffer based on the concentration of the sample
and where it falls on the standard curve. Be sure to add each standard and sample on the
plate in duplicate, at least. Solution A and B provided in the kit are mixed in a 1:50 ratio
of solution B to A and 200 µL of the mixture is added to each well. I would recommend
using a 300 µL multichannel pipette to do this as quickly and uniform as possible. This is
a light sensitive reaction; therefore, be sure to cover the plate and place it in aluminum foil
on the slow rocker. After 30 minutes, the plate is ran at 562 nm on the Spectramax located
in Catawba. Since the volume of each well is important when reading the absorbance, be
careful when transporting the plate across the street. Generally, I have found that there is
2-3 mg/mL protein isolated from epididymal fat collected from chow fed healthy male
C57Bl/6 mice, 4.5 mg/ml protein per 1x106 Raw 264.7 cells, 5 mg/ml protein per 1x106
3T3-L1 undifferentiated cells, and 13 mg/ml protein per 1x106 3T3-L1 differentiated cells
when cells were lysed in 100 µL of buffer.
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Once you have the absorbance values for the plate, upload them in Excel. The
standard curve will be plotted with the x axis as absorbance and y axis as concentration.
Be sure to average the absorbance values for each standard and subtract the background (0
mg/mL) from each prior to plotting. Add a linear trendline and equation to the graph. The
R2 value should be greater than 0.98. If it isn’t or you see that duplicate samples are not
similar, then I suggest repeating the assay and be sure to watch out for any pipetting errors.
The equation can then be used to solve for protein concentration (mg/mL) in the unknown
samples by plugging in the average absorbance value for each unknown (after subtracting
the background).
The amount of protein that you need to load to the gel will be dependent on the
protein of interest that you are analyzing. I suggest conducting an optimization western
blot where you analyze one sample from each group at different protein amounts loaded to
the gel in order to determine the appropriate loading amount. I suggest adding a positive
control in this optimization experiment as well. I had much success contacting Cell
Signaling for free positive controls for several antibodies. Most proteins that I have
analyzed in adipose tissue and cell lysate have been successful when adding 10-30 µg to
the gel.
To determine the volume of each sample needed to add to the gel (µL) that will
provide the appropriate amount of protein, divide the amount of protein that should be
added to the gel (µg) by the total concentration (µg/µL). The protein concentration and the
amount of protein desired to load will determine the total volume that should be added to
the gel. If it is greater than 25 µL, then the 10 well comb should be used during gel casting
as it can accommodate up to 45 µL. If 25 µL or less can be loaded and you have more than
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10 samples, the 15 well comb can be used during gel casting. The amount of sample buffer
(2X Biorad sample buffer+ β mercaptoethanol) should be half of the total volume.
Homogenization buffer should be added to make up the difference between the total
volume, sample, and sample buffer.
A.3 Gel preparation
The molecular weight of the protein of interest will dictate the percentage of
acrylamide in the gel that is used, such that the molecular weight and acrylamide
percentage are inversely proportional. When probing for higher molecular weight proteins
(100-250) kDa, I suggest casting an 8% acrylamide gel to ensure the greatest separation
between the top three standards. However, most of the proteins that we probe for will be
successful using a 10% gel (25-100 kDa). For smaller proteins, I suggest using a 15%
acrylamide gel. The separation gel is first made at the appropriate acrylamide percentage
using the recipe found on the google drive. Once the casting apparatus is set up, I suggest
adding the comb to the top to ensure you are aware how high to pour the stacking gel (it
should not be poured higher than the comb will allow). Methanol is added to the stacking
gel solution once it is poured using a 1 mL pipette so to remove any air bubbles. It normally
takes approximately 25 minutes for the solution to gel, which can be determined by
observing the leftover solution. Once it is gelled, the extra solution on the top is poured out
and the stacking gel solution is poured on the separating gel. The stacking gel is casted the
same way for every gel, no matter the acrylamide percentage. The comb of choice as
determined by experimental design must be added to the gel solution quickly after pouring.
Be sure the Biorad emblem on the comb is facing you when you slide it into the apparatus.
If it is backwards and you try to push it in it will break the glass cast. Furthermore, be sure
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there are no air bubbles in the comb as this can have a negative impact during well loading
and electrophoresis.
A.4 Buffer preparation
The main buffers needed to successfully run these experiments are running buffer,
transfer buffer, and tris buffered saline (TBS) and the recipes for each buffer is found on
the google drive. I suggest making a 5X stock of running buffer that can be diluted when
needed. Prior to making this stock, make a 10% solution of sodium dodecyl sulfate (SDS)
using the heated stir plate that you should then use to add the appropriate amount of SDS
to the 5x stock. Do not add solid SDS to the 5X running buffer stock as it is extremely
difficult to dissolve and stocks made with solid SDS have been associated with
electrophoresis issues. Transfer buffer is usually made the day of the experiment. Be sure
to pH the buffer prior to adding the appropriate amount of methanol. Most proteins that we
probe for in our lab require transfer buffer that contains 20% methanol; however, high
molecular weight proteins (>150 kDa) it is suggested to use transfer buffer containing 10%
methanol to prevent these proteins from precipitating out. I suggest making a 5X solution
of TBS using the recipe. To make TBST, the wash buffer, dilute this stock and add 10%
tween.
A.5 Sample preparation
In order to reduce proteins so that they can be ran on gel electrophoresis, samples
must be mixed with Laemmli sample buffer supplemented with β-mercaptoethanol and
heated at 100°C for 5 minutes. Turn the hot plate on first thing to allow ample time to reach
100°C. To make the sample buffer, first determine the total volume you need for your
experiment as determined in section A.2 and then make a solution that is 5% β-
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mercaptoethanol in 2x Laemmli sample buffer supplied from Biorad. According to the
calculations conducted in section A.2, mix the appropriate volumes of protein lysate, RIPA
buffer, and sample buffer and vortex to mix thoroughly. Make a hole in the cap of each
sample and place on the heating block for 5 minutes. During these 5 minutes, set up your
gel electrophoresis station.
A.6 Gel Electrophoresis
To set up your station, put the previously made gels in the gel electrophoresis cell
with the gel combs facing inward. If you are only running one gel, replace the second gel
with the running plate to ensure that running buffer will remain within the inner cell. Add
running buffer to the inner cell all the way to the top of the gel casts and then add running
buffer to the outside cell until it reaches the two-gel line. Carefully, remove the combs from
the gel cast and top off the inner cell with running buffer. Once the samples are removed
from the heating block, vortex the samples thoroughly in order to thoroughly break the
disulfide bonds. Quickly spin down the samples to collect all of the volume at the bottom.
I suggest putting the samples in the order in which you plan to load them into the gel as
this will make it easier to ensure they are in the proper order upon loading. Be careful with
this because once your samples are loaded, you have no way of confirming which sample
is in which lane. Add approximately 3 µL of Biorad ladder to the first lane in each well
and then add the appropriate volume of sample to each lane. Be careful to pipette the same
volume of each sample as this can cause differences in loaded protein content. Once you
are finished loading, place the electrophoresis cell lid on top ensuring that the black and
red rods are inserted into the black and red holes on the lid. Turn the powerpack on and set
it to 90V for the first 30 minutes and then increase the voltage to 125V until the ladder has
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separated the entire length of the gel. Bubbles will indicate that the gel is successfully
running. The time necessary for the gel to run is approximately 1.5 hours for a 10% gel;
however, this will change based on the acrylamide percentage in the gel.
A.7 Transfer
In my opinion, transfer can be the most difficult aspect of the experiment to perfect;
therefore, it may take a few trials to become comfortable with this part. First, transfer buffer
should be made fresh as stated in the protocol. Most proteins require transfer buffer that
contains 20% methanol; however, extremely high molecular weight proteins (>250), for
example, acetyl co-A-carboxylase (280 kDa), should be transferred using transfer buffer
containing 10% methanol, as methanol can cause high molecular weight proteins to
precipitate out during transfer. Prior to removing the gels from the running tank, place the
transfer tank in a Styrofoam box, pack ice around the tank, and place an icepack in the
transfer tank. Then gather the appropriate number of transfer cassettes (red and black)
(1/gel), black sponges (2/gel), filter paper (2/gel), nitrocellulose membrane (1/gel) and
transfer container. Be sure to cut the nitrocellulose membrane to as similar size to the gel
as possible and submerge in transfer buffer. Submerge the filter paper and black sponges
in the transfer buffer and then arrange the transfer cassette where the assembly is completed
on the black portion of the cartridge (i.e. black is closest to you). Once the protein is
sufficiently separated, gels can be removed from the running tank. Gently crack the gel
open, scrape off the wells and transfer the gel from the cast into transfer buffer until ready
to load into the transfer cassette. Then assemble the sponges, gel, membrane, and filter
paper in the transfer cassette as follows: black sponge, filter paper, gel, nitrocellulose
membrane, filter paper, and black sponge. Be sure to roll out any air bubbles between each
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layer to ensure protein transfer. The proteins will transfer from left to right; therefore, when
you place the assembled cassette in transfer tank it is important for the red side to face to
the right so that the protein can travel from the gel into the membrane. Add transfer buffer
until the fill line and run the apparatus at 25V overnight (approximately 17 hours). If
running multiple gels, be sure to mark down which slot which gel was transferred in.
Additionally, smaller proteins may over transfer; therefore, for low molecular weight
proteins (>20 kDa), I suggest transferring for 3 hours instead of overnight. Once the
transfer is complete, remove the gel and nitrocellulose membrane and use the gel outline
to cut any excess membrane. Then remove the membrane, place it in a labeled plastic blot
container with TBST, and wash for 5 minutes to remove any residual transfer buffer. From
this point, if the membrane dries out it is unusable; therefore, ensure that the blot is always
submerged.
A.8 Immunoblotting
In order to block nonspecific binding, add 5% nonfat milk to each blotting container
and allow to incubate at room temperature on the rocker for 1 hour. Remove the milk and
wash with TBST for 1 minute to remove all excess milk. Most primary antibodies that we
purchase from Abcam or Cell Signaling are used at 1:1000 dilution in 5% BSA. Add the
primary antibody solution to all blots and allow to rock in the refrigerator overnight. The
next day, remove the primary antibody and wash in TBST for 20 minutes and repeat 2 more
times. Primary antibodies will either be grown in rabbit or mouse; therefore, will require
an anti-rabbit or anti-mouse secondary antibody. Both antibodies are used at 1:2000
dilution in 5% milk supplemented with 1:5000 dilution of the Biorad ladder secondary.
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Blots are incubated at room temperature on the rocker for 1 hour and then washed with
TBST for 4 times 15 minutes.
A.9 Imaging blot using ChemiDoc
The western blot imager is found in Catawba. When turning the machine on be sure
to turn on the imager and camera a few minutes prior to turning the computer on to ensure
a connection. Wipe down the imager before and after use with 70% ethanol. Upon opening
the ImageLab software, take the following actions:
-

New protocol

-

Application -> Select -> Blots -> Chemi hi resolution

-

Imaging Area -> Bio-Rad Criterion Gel

-

Set the appropriate exposure time

To develop the signal, mix a 1:1 ratio of each component of the chemiluminescent
substrate. Then exchange the TBST on the blot for chemiluminescent substrate and
incubate for 2 minutes while rocking the blot. Be sure to do this in the dark to prevent
photobleaching. Using the forceps, gently place the membrane on the imager and ensure
its proper positioning by selecting position gel on the software. Once appropriately placed,
expose the blot for the appropriate amount of time determined by the saturation of the band
of interest. I suggest using the exposure setting where you set how many images the camera
takes in a certain time period. Imaging exposure times will vary depending on protein of
interest. Most proteins that I have measured use an exposure time between 5-60 seconds.
If the blot needs to be stripped and probed for a different protein, place the blot back in the
plastic container submerged in TBST to ensure the blot doesn’t dry out. If not, the blot can
be disposed.
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A.10 Probing for second protein
Wash the blot in TBST for 10 minutes to remove any residual chemiluminescent
substrate that may still be on the blot and then incubate the blot in 4 mL Biorad stripping
buffer for 25 minutes at room temperature on the rocker. This stripping buffer contains βmercaptoethanol; therefore, it is necessary to excessively wash the blot in TBST to remove
any residual β-mercaptoethanol that may interfere in the immunoblotting process. I
recommend washing the blot at least 4 times in TBST for 5 minutes each time. Continue
the immunoblotting and analysis process as previously stated for the next protein.
Generally, this is GAPDH or β-actin, which are both incubated at 1:5000 dilutions in 5%
BSA. GAPDH requires the rabbit secondary antibody and β-actin requires the mouse
secondary antibody.
A.11 Analyzing intensity of bands using Image Lab
ImageLab software can be downloaded for free directly from the Biorad website so
that you can analyze the intensity of your band on your own computer. Once you have
opened the file, select Lane and Bands in the Analysis Toolbox, and then select to manually
indicate the lanes. Indicate the number of lanes of samples that you will analyze and then
manipulate the lanes so that each lane contains only one band and is the appropriate width
for that band. In the newest version of ImageLab, to change the width of the lane, you need
to select Bands from the Lane and Bands toolbox, select a lane and then return to Lanes.
Once you have the lanes in the proper place, select Bands, Add and then click on your
bands on interest. Clicking Adjust in the toolbox will allow you to ensure that the height
of each band contains the entire band and that all heights are the same. Once this is
accomplished, click Analysis Table from the top toolbar and a table will be displayed on
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the bottom of the screen. Copy the adjusted intensity for each lane into a new excel
spreadsheet and normalize the intensity of the protein of interest by the total protein if
looking at a phosphorylation site or the housekeeping protein (i.e. GAPDH or β-actin).
The intensity of the housekeeping protein should be approximately the same between each
sample on the gel.
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APPENDIX B
BEST PRACTICES FOR FLOW CYTOMETRY EXPERIMENTS
Flow cytometry is a powerful technique that uses cell surface markers to measure
the prevalence of different cell populations within a parent cellular suspension. During my
time in the lab, I used flow cytometry to determine the number of different immune cell
populations found within the adipose tissue after PLG scaffold implant. Additionally, I
used this tool to determine the purity of porcine derived adipose tissue stem cells and bone
marrow derived macrophages. This section will go into detail of best practices to ensure
while conducting flow cytometry experiments.
B.1 Designing flow cytometry panels and controls
When designing a flow cytometry experiment, it is necessary to first determine the
purpose of the experiment, the cell surface markers needed, and the capabilities of your
flow cytometer. For this example, the purpose of your experiment is to quantify the number
of macrophages in the adipose tissue. We must first consider the capabilities of our
equipment. We use the BD FACS Aria II flow cytometer located at the University of South
Carolina Medical School. This machine contains 488 and 640 lasers with filters for FITC,
PE, PE-Texas Red, and PE-Cy7 on the 488 laser and APC and APC-Cy7 on the 640 laser.
Therefore, your staining cocktail can only contain a maximum of six markers; however,
we determined that PE-Texas Red and PE signal significantly overlap; therefore, I suggest
using only FITC, PE, PE-Cy7, APC and APC-Cy7 labeled antibodies in the development
of your panel. The commonly used surface markers for macrophages is CD11b and F4/80.
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However, you determine that you need to first isolate the immune cells within the tissue;
therefore, you also need CD45 as a global immune cell marker. Therefore, you need three
antibodies each labeled with a different fluorochrome that can be analyzed by the flow
cytometer. If you had decided to quantify several immune cell populations including
macrophages, neutrophils, monocytes, T cells, B cells and natural killer cells you would
need antibodies for the surface markers for each cell population, including CD45 (total
immune cells), CD11b (monocytes, macrophages), Ly6G (neutrophils), F4/80
(macrophages), CD3 (T cells), CD19 (B cells), and NK1.1 (natural killer cells). The flow
cytometer, however, does not have the capabilities to analyze all seven antibodies. To
overcome this, you can split the sample in half and run either a lymphocyte panel or
myeloid panel. Each panel would incorporate a dump gate, where all markers for the other
cell types would be added with the same fluorochrome label. For example, all myeloid or
lymphocyte lineage markers would be stained with one color and the other lineage markers
would be stained with individual fluorochromes.
The concentration of each antibody and the recommended amount to use for staining
is usually found on the supplier’s website. Most of our flow cytometry antibodies are
purchased from Biolegend. For example, CD45-FITC comes at a 0.5 mg/ml concentration
and is recommended to use less than or equal to 0.25 µg per 106 cells. Use these values to
back calculate the volume of antibody that needs to be added to stain each sample.
However, it is suggested that you titrate the antibody to determine the concentration that
provides the largest difference in stained and unstained sample. In my experience, using
half of the recommended antibody will be appropriate for staining.
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There are specific controls that must be incorporated into your flow cytometry
experimental design in addition to the samples that will receive the master mix (i.e. the
staining cocktail). To remove any emission spectra overlap between different
fluorochromes, single fluorochrome compensation controls must be included. These
controls are developed when you stain either a small portion of your sample or beads with
each fluorescently labeled marker individually. The main thing to consider here is that
whatever you stain must be as fluorescently bright as your mastermix stained samples in
order to compensate appropriately. Additionally, you will also need an unstained sample
to use for compensation. These blank samples will also help you determine where your
negative populations are as well as determine the level of potential autofluorescence.
Finally, the use of fluorescent minus one control samples will aid in determining the
appropriate gating scheme. To develop these controls, you will stain a small portion of your
sample with a mastermix including all fluorescently labeled markers except for one which
will be the isotype control of that particular antibody labeled with the same fluorochrome
as the marker you are using in the mastermix. You will have as many isotype control
labeled samples as the number of markers in your panel design. The isotype control
information for each antibody is also found on the supplier’s website.
B.2 Preparing samples for staining
The main type of cells that we have analyzed via flow cytometry have been isolated
from whole blood, tissues, or cell cultures. Whole blood and cells collected from cultures
do not need any additional processing prior to staining; however, tissues must be digested
prior to staining. To digest tissues, inject Liberase, which is a combination of collagenase
1 and collagenase II, directly into the tissue. The tissue should become clearer as you inject
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indicating that the cells are being removed from the tissue. Then mince the tissue into tiny
pieces and incubate in the oven for 20 minutes to activate the liberase. The addition of
EDTA will stop the reaction for the samples to then be strained through a 100 µm filter to
remove any undissociated pieces. Cells can then be collected, washed via centrifugation,
and transferred to polypropylene flow tubes for subsequent staining. All samples should be
kept in ice until analyzing on the flow cytometer unless otherwise stated. If the tissue is a
highly vascularized tissue such as the liver, the red blood cells also need lysed using ACK
buffer. If multiple people are dissociating samples from the same experiment, be sure to
keep track of who prepared which samples in case there is any variability. Additionally, a
small experiment was conducted in 2017 that aimed to compare adipose tissue dissociation
using liberase or collagenase 1 and the results indicated that the number of total immune
cells was not significantly different in tissues isolated using either digestion method.
However, I suggest that this experiment be repeated if this question still remains because
the variability using collagenase 1 was high.
B.3 Staining samples
Various immune cell populations including macrophages, monocytes, B cells, and
granulocytes express FC receptors, CD16 and CD32, on their surface. In order to prevent
non-specific binding to these FC receptors, cells are first incubated with anti-mouse
CD16/32 antibody that is not fluorescently labeled. Samples are then incubated with the
appropriate antibody cocktail as determined during your panel design. From this point on
be sure to keep stained samples in the dark to prevent photobleaching. The unbound
antibodies are then removed via centrifugation. Fixing the tissues using fixation buffer
purchased from Biolegend will allow for the samples to be kept overnight if you aren’t able
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to analyze the samples on the flow cytometer until the next day. If they are kept in the dark
at 4°C, I suggest analyzing them on the flow cytometer within 24-48 hours maximum. If
the sample is whole blood, the red blood cells can be lysed and fixed simultaneously using
Biolegend’s Lyse/Fix buffer. Samples are then washed thoroughly and transferred to the
filter cap polystyrene flow cytometry tubes to remove any debris. Lastly, if using counting
beads to calculate the number of each cell population, the exact volume of the sample to
be analyzed on the flow cytometer must be recorded. I suggest pipetting the sample into a
new polypropylene flow cytometry tube to determine the volume. The samples are
prepared to be analyzed on the flow cytometer. Carefully, transport the samples on ice,
counting beads, 100 µL pipette and tips to the medical school.
B.4 Running the samples on the flow cytometer
The BD FACS Aria II flow cytometer and cell sorter is located at the University of
South Carolina Medical School and is housed in the Instrument Resource Facility. Kia
Zellers is the point of contact for any questions that you may have regarding the machine
and is responsible for flow cytometer maintenance, such as refilling the sheath fluid or
emptying the waste. You will need to contact her for proper flow cytometer training that
will then allow you to independently use the machine. Like all IRF equipment, the flow
cytometer must be scheduled prior to use and can be done so on the ILabs solutions website.
I highly suggest scheduling the flow cytometer for longer than you anticipate.
Turn the flow cytometer and laser on using the buttons on the left side of the flow
cytometer. Open the BD FACSDiva software on the computer and begin setting up your
experiment. Under the “Gower Lab” folder, create a new experiment and label it
appropriately. Then add a specimen underneath this experiment and label appropriately.
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You can add multiple “specimens” to the same experiment folder if you are running several
similar experiments in a short period of time. Then under the specimen, add a sample for
each sample that you have prepared to run on the flow cytometer and rename each
appropriately. Next turn the flow stream on by clicking the red X on the top of the stream
and wait until the drops are even. If these samples have been ran before, then you most
likely will have a good idea of the fluorochrome settings that should be used and the dot
plots that need to be created; however, if this is the first time that you are running these
samples, I suggest making an extra mastermix stained sample to use to determine the
appropriate fluorochrome settings (under cytometer settings, parameters). Fluorochromes
fluorescent intensity is on a log scale and forward and side scatter are on a linear scale.
Knowing which cell populations you are interested in will allow you to initially create dot
plots and target populations within those dot plots. For example, if you are analyzing the
number of macrophages within the sample, you know those cells are positive for CD11b
and F4/80. Therefore, you first make an FSC versus SSC plot and gate out any debris likely
located at the origin. You can then plot that population on the fluorochromes that CD11b
and F4/80 are labeled and gate the double positive population. Once you have created the
dot plots for all the target cells, vortex and then load the extra sample to begin acquisition.
Additionally, I suggest running this extra sample at a low flowrate (< 3), located on the
bottom toolbar, in order to have enough time and sample to determine the settings. Once
acquisition begins, you will see dots collecting on your dot plots, indicating cells. Alter the
settings to ensure that all of your cells are located and appropriately spread out on the FSC
versus SSC dot plot and that each fluorochrome positive cells are located at approximately
103 on the log scale. Be sure to also record forward scatter height and width (FSC-H, FSC-

136

W) and side scatter height and width (SSC-H, SSC-W) in order to remove any doublet cell
populations in the analysis. The other settings that are normally changed are found on the
bottom toolbar, including number of events shown in your dot plots on the right panel,
number of events recorded either total or in a particular population, and the flow rate.
Events are equivalent to the number of cells that have passed through the laser and it is
good practice to record as many events in your sample as possible. I suggest recording a
minimum of 5,000 events in each target cell population if possible. I normally select to
show 1,000,000 so that all of the events will show on the dot plots. Additionally, I do not
suggest running the sample at a flow rate higher than 5, as running the samples at a high
flow rate can increase the variability due to the position of the cells within the laser (i.e.
more groups and less individual cells). Furthermore, by adding a population statistics table,
the software will tell you the number of events that are in each population as you run your
sample.
Once you have determined your settings and created your dot plots and populations,
you can start recording your various samples. After loading the sample and the event rate
is stable (approximately 5 seconds), click record to record your data. If you do not click
record, your data will not be saved. You have the liberty to analyze any sample in any
order; however, I suggest starting with your FMO controls to ensure that your gating
scheme is appropriate and then move on to your mastermix stained samples. If you are
using counting beads, add the beads prior to vortexing and then load the sample. Counting
beads are fluorescent in all channels; however, the best gate that I have found for locating
the counting beads is located on SSC versus APC. Finally, record the blank and
compensation samples. All samples must be analyzed using the same settings. Collect the
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data by right clicking the specimen and exporting onto your flash drive. I always save both
the 2.0 and 3.0 versions just in case; however, I use the 2.0 version during the analysis.
B.5 Analyzing samples using FlowJo
To analyze data using FlowJo, drag and drop files into FlowJo. Because you may
have a large number of files to analyze, I suggest first organizing the data based on sample
groupings (i.e. mastermix stained, blanks, compensation controls, and isotype controls) by
clicking Create New Groups of Samples and dragging and dropping the files into the
appropriate groups. Then using your compensation samples, gate on your positive and
negative populations for the fluorochrome used to stain that sample. Ensure that your
positive populations are as bright in each channel as your sample. If they aren’t, you will
need to repeat the compensation controls using a different sample with the same settings
that was used to analyze the main sample. To develop a compensation matrix that can then
be applied to the rest of your samples, click Platform, Compensate Samples, then Define
New Matrix. Drag and drop your positive and negative gates for the appropriate
fluorochrome into the table and then click Compute & Close. To apply the compensation
matrix to the rest of your samples, select all samples then Platform, Compensate Samples,
and the title of your compensation matrix. You should see a colored bar to the left of each
sample denoting that it was compensated.
Next, use your isotype controls to develop the appropriate positive gates that you will
then apply to your mastermix stained samples. Use forward scatter vs side scatter plot to
determine the main cell population as there maybe cell debris located at the origin that
should be gated out. Then gate out doublets by gating side scatter width versus side scatter
height. Looking back at our macrophage panel example, one isotype control will be stained

138

with the isotype control for CD45, CD11b, or F4/80. Use the sample stained with the CD45
isotype control to determine where the positive gate for CD45 should be located. Complete
this analysis for the samples stained with the CD11b or F4/80 isotype control as well. Then
copy and paste the gating scheme developed using the isotype controls onto the mastermix
stained samples.
There are different methods of reporting flow cytometry data that are commonly
used. Dot plots are a convenient way to illustrate significant and obvious differences
between groups. An easy way to compare dot plots between groups is to use the layout
function to compare representative samples from each group side by side. Histograms are
also a common method to depict how mean fluorescent intensities shift between groups.
The layout function will also allow you to overlay histograms from different samples so
that they can be compared on a single plot. Furthermore, the number of cells in each cell
population can be used along with the counting bead concentration and sample volume to
calculate the number of total cells in each population in the total sample. This cellular
quantification allows for statistical analysis between groups. Finally, the average mean
fluorescent intensity of each sample can be determined using the statistic function and can
then be averaged and statistically compared between groups. This is particularly useful
when investigating the presence of a marker on a particular cell type.
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APPENDIX C
MANUSCRIPT COPYRIGHTS

Figure C.1: Screenshot of permission from ACS Journals to reuse published work
in this dissertation.
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